Food and Chemical Toxicology 42 (2004) 157–185
www.elsevier.com/locate/foodchemtox
Review
The FEMA GRAS assessment of cinnamyl derivatives used as
flavor ingredients
Timothy B. Adamsa,*,2, Samuel M. Cohenb,1, John Doullc,3, Victor J. Ferond,1,
Jay I. Goodmane,1, Lawrence J. Marnettf,1, Ian C. Munrog,4, Philip S. Portogheseh,1,
Robert L. Smithi,1, William J. Waddellj,1, Bernard M. Wagnerk,l,1
a
Flavor and Extract Manufacturers Association, 1620 I Street, N.W., Suite 925, Washington, DC 20006, USA
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, USA
c
Department of Pharmacology and Toxicology, University of Kansas Medical Center, Kansas City, Kansas, USA
d
TNO Nutrition & Food Research Institute, Toxicology, Utrechtseweg 48, The Netherlands
e
Department of Pharmacology and Toxicology, Michigan State University, B440 Life Science Building, East Lansing, Michigan, USA
f
Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
g
CanTox, Inc., Mississauga, Ontario, Canada
h
Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota, USA
i
Division of Biomedical Sciences Section of Molecular Toxicology, Imperial College School of Medicine, South Kensington, London SW7 2AZ, UK
j
Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky, USA
k
New York University, School of Medicine, New York, New York, USA
l
Bernard M. Wagner, Associates, Millburn, New Jersey, USA
b
Received 2 July 2003; received in revised form 21 August 2003; accepted 31 August 2003
Abstract
This publication is the seventh in a series of safety evaluations performed by the Expert Panel of the Flavor and Extract Manufacturers Association (FEMA). In 1993, the Panel initiated a comprehensive program to re-evaluate the safety of more than 1700
GRAS flavoring substances under conditions of intended use. Elements that are fundamental to the safety evaluation of flavor
ingredients include exposure, structural analogy, metabolism, pharmacokinetics and toxicology. Flavor ingredients are evaluated
individually and in the context of the available scientific information on the group of structurally related substances. Scientific data
relevant to the safety evaluation of the use of cinnamyl derivatives as flavoring ingredients is evaluated.
# 2003 Elsevier Ltd. All rights reserved.
Abbreviations: ABS, chromosomal aberration; ADH, alcohol dehydrogenase; ALD, aldehyde dehydrogenase; B. subtilis, Bacillus subtilis; CHO,
Chinese hamster ovary; CoA, coenzyme A; DNA, deoxyribonucleic acid; ECETOC, European Centre for Ecotoxicology and Toxicology of Chemicals; E. coli, Escherichia coli; F, Female; FDA, United States Food and Drug Administration; FEMA, The Flavor and Extract Manufacturers
Association; GRAS, Generally Recognized as Safe; GRASa, GRAS affirmed; GRASr, GRAS reaffirmed; IARC, International Agency for Research
on Cancer; i.p., intraperitoneal; LD50, median lethal dose; M, Male; MLA, mouse lymphoma cell assay; NAS, National Academy of Science; NCI,
National Cancer Institute; NOEL, No observed effect level; NR, Not reported; NTP, National Toxicology Program; PPARa, peroxisome
proliferator-activated receptor a; PE, polychromatic erythrocytes; ppm, parts per million; S. typhimurium, Salmonella typhimurium; SCE, sister
chromatid exchanges; SLR, scientific literature review.
* Corresponding author. Tel.: +1-202-293-5800; fax: +1-202-463-8998.
E-mail address: tadams@therobertsgroup.net (T.B. Adams).
1
The authors are members of the FEMA Expert Panel.
2
Scientific Secretary to the FEMA Expert Panel.
3
Emeritus member of the FEMA Expert Panel
4
Consultant to the FEMA Expert Panel.
0278-6915/$ - see front matter # 2003 Elsevier Ltd. All rights reserved.
doi:10.1016/j.fct.2003.08.021
158
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
Contents
1. Chemical identity ....................................................................................................................................................................... 158
2. Exposure .................................................................................................................................................................................... 158
2.1. Flavor use and natural occurrence ....................................................................................................................................158
3. Hydrolysis, absorption, distribution, excretion and metabolism................................................................................................ 164
3.1. Hydrolysis.......................................................................................................................................................................... 164
3.2. Absorption, distribution and excretion .............................................................................................................................164
3.3. Metabolism........................................................................................................................................................................ 165
3.3.1. Cinnamyl alcohol and cinnamaldehyde derivatives............................................................................................... 165
3.3.2. Cinnamic acid........................................................................................................................................................ 166
3.3.3. Ring and chain substituted cinnamyl derivatives ..................................................................................................167
3.3.4. Cinnamyl anthranilate ........................................................................................................................................... 167
4. Toxicological studies .................................................................................................................................................................. 168
4.1. Acute toxicity .................................................................................................................................................................... 168
4.2. Short-term toxicity ............................................................................................................................................................ 168
4.3. Carcinogenicity studies on cinnamyl anthranilate, cinnamaldehyde, and anthranilic acid ............................................... 171
4.3.1. Cinnamyl anthranilate ........................................................................................................................................... 171
4.3.2. trans-Cinnamaldehyde ........................................................................................................................................... 174
4.3.3. Conclusion............................................................................................................................................................. 174
4.4. Genotoxicity studies .......................................................................................................................................................... 175
4.4.1. In vitro .................................................................................................................................................................. 175
4.4.2. In vivo ................................................................................................................................................................... 178
4.4.3. Conclusion............................................................................................................................................................. 180
4.5. Other relevant studies........................................................................................................................................................ 180
5. Recognition of GRASr status .................................................................................................................................................... 181
6. Correction .................................................................................................................................................................................. 181
References ....................................................................................................................................................................................... 181
1. Chemical identity
This summary presents the key data relevant to the
safety evaluation of cinnamyl alcohol, cinnamaldehyde,
cinnamic acid (trans-3-phenylpropenoic acid), and 53
structurally related substances for their intended use as
flavoring substances (Table 1). All members of this
group are primary alcohols, aldehydes, or carboxylic
acids, or their corresponding esters and acetals. The
primary oxygenated functional group is located on a
three-carbon saturated or unsaturated (i.e., at the 2,3position) chain with a benzene ring at the 3 position
(i.e., a 3-phenylpropyl or 3-phenyl-2-propenyl group).
The aromatic ring also may be substituted with alkyl,
alkoxy, or hydroxy substituents.
2. Exposure
2.1. Flavor use and natural occurrence
The total annual volume of the 56 cinnamyl derivatives used as flavoring ingredients is approximately
485,050 kg in the USA. (Lucas et al., 1999; NAS, 1970;
1982; 1987) (see Table 1). Approximately 93% of the
total annual volume in the USA is accounted for solely
by cinnamaldehyde (No. 22). Production volumes and
intake values for each substance are reported in Table 1.
Cinnamyl compounds are a fundamental part of plant
biochemistry. trans-Cinnamic acid is ubiquitous in the
plant kingdom and is required for lignin formation in
plants. It is derived from the action of l-phenylalanine
ammonia lyase upon l-phenylalanine, forming ammonia and cinnamic acid (Goodwin and Mercer, 1972).
Cinnamic acid is also converted to p-hydroxy cinnamic
acid (p-coumaric acid) by plants. p-Coumaric acid is one
of the more important precursors of lignins as it can be
converted to polyphenolic alcohols which readily polymerize to form lignin (Goodwin and Mercer, 1972).
Twenty-two of the 56 flavoring substances in this group
have been detected as natural components of traditional
foods (Maarse et al., 1999) (See Table 1). Quantitative
natural occurrence data have been reported for 3-phenylpropyl acetate (No. 3), ethyl 3-phenylpropionate (No. 9),
cinnamyl alcohol (No. 12), cinnamaldehyde (No. 22),
cinnamic acid (No. 23), methyl cinnamate (No. 24), and
159
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
Table 1
Identity and exposure data for cinnamyl derivatives used as flavor ingredients
Flavoring ingredient
FEMA
No.
CAS No.
and structure
Most recent
annual volume,
kga
Daily per capita intake
(‘‘eaters only’’)
mg/d
mg/kg bw/d
236
31
0.5
Annual volume in
naturally
occurring foods,
kgb
Consumption
ratioc
+
NA
2885
1. 3-Phenyl-1-propanol
2. 3-Phenylpropyl formate
2895
6d
1
0.02
3. 3-Phenylpropyl acetate
2890
68
9
0.1
140
2
4. 3-Phenylpropyl propionate
2897
2
0.3
0.005
+
NA
5. 3-Phenylpropyl isobutyrate
2893
122
16
0.3
NA
6. 3-Phenylpropyl isovalerate
2899
0.5d
0.1
0.001
NA
7. 3-Phenylpropyl hexanoate
2896
3d
0.5
0.008
NA
8. Methyl 3-phenylpropionate
2741
23d
4
0.07
NA
9. Ethyl 3-phenylpropionate
2455
0.5
0.06
0.001
47
94
10. 3-phenylpropionaldehyde
2887
145
19
0.3
+
NA
11. 3-Phenylpropionic acid
2889
4
0.5
0.008
+
NA
NA
(continued on next page)
160
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
Table 1 (continued)
Flavoring ingredient
FEMA
No.
CAS No.
and structure
Most recent
annual volume,
kga
Daily per capita intake
(‘‘eaters only’’)
mg/d
mg/kg bw/d
Annual volume in
naturally
occurring foods,
kgb
Consumption
ratioc
171
0.012
12. Cinnamyl alcohol
2294
14651
1930
32
13. Cinnamaldehyde ethylene
glycol acetal
2287
0.05
0.006
0.0001
NA
14. Cinnamyl formate
2299
127
17
0.3
NA
15. Cinnamyl acetate
2293
2250
296
5
16. Cinnamyl propionate
2301
191
25
0.4
17. Cinnamyl butyrate
2296
17
2
0.04
18. Cinnamyl isobutyrate
2297
163
22
0.4
NA
19. Cinnamyl isovalerate
2302
64
8
0.1
NA
5d
1
0.01
NA
NA
20. Cinnamyl benzoate
+
NA
NA
+
NA
21. Cinnamyl phenylacetate
2300
10
1
0.02
22. Cinnamaldehyde
2286
450417
59328
989
38642
0.09
23. Cinnamic acid
2288
331
44
0.7
183
1
161
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
Table 1 (continued)
Flavoring ingredient
FEMA
No.
CAS No.
and structure
Most recent
annual volume,
kga
Daily per capita intake
(‘‘eaters only’’)
mg/d
mg/kg bw/d
Annual volume in
naturally
occurring foods,
kgb
Consumption
ratioc
24. Methyl cinnamate
2698
6305
830
14
57
0.009
25. Ethyl cinnamate
2430
481
63
1
292
1
26. Propyl cinnamate
2938
31
4
0.07
NA
27. Isopropyl cinnamate
2939
23
3
0.05
NA
28. Allyl cinnamate
2022
2
0.2
0.004
NA
29. Butyl cinnamate
2192
1
0.2
0.003
NA
30. Isobutyl cinnamate
2193
21
3
0.05
+
NA
31. Isoamyl cinnamate
2063
45
6
0.1
+
NA
32. Heptyl cinnamate
2551
390d
69
1
NA
33. Cyclohexyl cinnamate
2352
0.3
0.04
0.001
NA
34. Linalyl cinnamate
2641
19
2
0.04
NA
(continued on next page)
162
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
Table 1 (continued)
Flavoring ingredient
FEMA
No.
CAS No.
and structure
Most recent
annual volume,
kga
Daily per capita intake
(‘‘eaters only’’)
mg/d
mg/kg bw/d
Annual volume in
naturally
occurring foods,
kgb
Consumption
ratioc
35. Terpinyl cinnamate
3051
4d
0.7
0.01
36. Benzyl cinnamate
2142
526
69
1
37. Phenethyl cinnamate
2863
381
50
0.8
NA
38. 3-Phenylpropyl cinnamate
2894
281
37
0.6
NA
39. Cinnamyl cinnamate
2298
277
36
0.6
40. -Amylcinnamyl alcohol
2065
9
1
0.02
NA
41. 5-Phenylpentanol
3618
1d
0.2
0.004
NA
42. -Amylcinnamyl formate
2066
4d
0.7
0.01
43. -Amylcinnamyl acetate
2064
1991
263
4
NA
44. -Amylcinnamyl isovalerate
2067
4d
0.7
0.01
NA
45. 3-Phenyl-4-pentenal
3318
16d
2
0.04
NA
46. 3-(p-Isopropylphenyl)
propionaldehyde
2957
1
0.2
4
NA
NA
+
+
NA
NA
163
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
Table 1 (continued)
Flavoring ingredient
47. a-Amylcinnamaldehyde
dimethyl acetal
48. p-Methylcinnamaldehyde
FEMA
No.
2062
3640
CAS No.
and structure
Most recent
annual volume,
kga
Daily per capita intake
(‘‘eaters only’’)
Annual volume in
naturally
occurring foods,
kgb
Consumption
ratioc
mg/d
mg/kg bw/d
0.05
0.006
0.0001
NA
7d
1
0.02
NA
49. a-Methylcinnamaldehyde
2697
2926
385
6
+
NA
50. a-Butylcinnamaldehyde
2191
0.5d
0.08
0.001
+
NA
51. a-Amylcinnamaldehyde
2061
172
23
0.4
+
NA
52. a-Hexylcinnamaldehyde
2569
82
11
0.2
+
NA
53. p-Methoxycinnamaldehyde
3567
1510d
265
4
+
NA
54. o-Methoxycinnamaldehyde
3181
540
71
1
+
NA
55. p-Methoxy–methylcinnam
aldehyde
3182
0.4d
0.06
0.001
NA
56. Cinnamyl anthranilate
2295
163d
29
0.5
NA
a
Intake (mg/person/day) calculated as follows: [(annual volume, kg)(1109 mg/kg)]/[populationsurvey correction factor365 days], where population (10%,
‘‘eaters only’’)=26106 for the U.S.A.; where correction factor=0.6 for NAS surveys and 0.8 for the Lucas et al. U.S.A. survey representing the assumption that only
60% and 80% of the annual flavor volume, respectively, was reported in the poundage surveys (Lucas et al., 1999; NAS, 1970,1982, 1987). Intake (mg/kg bw/d) calculated as follows: [(mg/person per day)/body weight], where body weight=60 kg. Slight variations may occur from rounding.
b
Quantitative data for the United States reported by Stofberg and Grundschober, 1987
c
The consumption ratio is calculated as follows: (annual consumption via food, kg)/(most recent reported volume as a flavoring substance, kg); NA=data not available.
d
Annual volume reported in previous U.S.A. surveys (NAS, 1970, 1982, 1987).
164
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
ethyl cinnamate (No. 25), and indicate that intake of these
substances are predominately from food (i.e., consumption ratio > 1) (Stofberg and Kirschman, 1985; Stofberg
and Grunschober, 1987). Cinnamaldehyde has been
detected in the oils derived from natural sources such as
cinnamon, cinnamomum, and cassia leaf at levels up to
750,000 ppm (Maarse et al., 1999).
3. Hydrolysis, absorption, distribution, excretion and
metabolism
3.1. Hydrolysis
Esters and acetals formed from the parent alcohol,
aldehyde, or carboxylic acid are hydrolyzed prior to or
during or after absorption. Once formed, cinnamyl
alcohol, cinnamaldehyde and cinnamic acid have all
been shown to be rapidly absorbed from the gut, metabolized and excreted primarily in the urine and, to a
minor extent, in the feces. Results of numerous studies
indicate that cinnamyl derivatives are absorbed, metabolized and excreted as polar metabolites within 24 h.
In general, esters containing an aromatic ring system
are hydrolyzed in vivo by classes of enzymes recognized as carboxylesterases or esterases (Heymann,
1980), the most important of which are the A-esterases.
In mammals, A-esterases occur in most tissues
throughout the body (Anders, 1989; Heymann, 1980)
but predominate in the hepatocytes (Heymann, 1980).
Acetals are rapidly hydrolyzed in acidic medium
(Morgareidge, 1962).
Esters of cinnamic acid and structurally related aromatic esters have been shown to hydrolyze rapidly to
the component acid and alcohol. Oral administration of
a single dose of 50 mg methyl cinnamate (No. 24)/kg bw
resulted in the urinary excretion, after 24 h, of hippuric
acid (66%) and benzoylglurcuronide (5%). This distribution of metabolites, nearly identical to that for
cinnamic acid, indicates that rapid hydrolysis of the ester
in vivo precedes metabolism of the acid (Fahelbum and
James, 1977). Ethyl cinnamate (No. 25) administered
subcutaneously to a cat also produced only cinnamic
acid metabolites in the urine (Dakin, 1909). Incubation of benzyl cinnamate (No. 36) or benzyl acetate
with simulated intestinal fluid (pH 7.5; pancreatin) at
37 C for 2 h resulted in 80 and 50% hydrolysis,
respectively (Grundschober, 1977). in vitro incubation
of the structurally related aromatic acetal, 2-phenylpropanal dimethyl acetal (1 mM) with simulated gastric juice at 37 C resulted in 97% hydrolysis in 1 h.
Under the same experimental conditions, benzaldehyde propylene glycol acetal (1 mM) was 97% hydrolyzed in 5 h when compared with a blank incubation
of the acetal and 0.1 N HCl under reflux (Morgareidge, 1962).
3.2. Absorption, distribution and excretion
In male Fischer 344 (F344) rats (4/group), 83%,
77%, or 79% of an oral dose of 2.5 mmol/kg bw of
[3-14C-d5]-cinnamyl alcohol (335 mg/kg bw), [3-14C-d5]cinnamaldehyde (330 mg/kg bw), or [3-14C-d5]-cinnamic acid (370 mg/kg bw), respectively, is excreted
primarily in the urine within 24 h. Excretion in the
feces accounted for only minor amounts of the administered alcohol (6.1%), aldehyde (15.8%), or acid
(0.9%). Greater than 90% of the administered dose of
any of the three substances is recovered in the urine
and feces within 72 h. Administration of the same
doses of the parent alcohol, aldehyde, or acid to groups
of CD-1 mice by intraperitoneal injection results in
a similar pattern of excretion in the urine and feces at
24 (75, 80 and 93%, respectively) and 72 h (> 93%)
(Nutley, 1990).
In a study (Sapienza et al., 1993) of tissue distribution
and excretion of cinnamaldehyde, male F344 rats (8/
group) were pretreated with single daily oral doses of 5,
50, or 500 mg/kg bw of cinnamaldehyde by gavage for 7
days. Twenty-four hours later, animals in each group
received a single oral dose of [3-14C]cinnamaldehyde
equivalent to the pretreatment level. Groups of rats (8/
group) receiving no pretreatment were also given single
oral doses of 5, 50 or 500 mg/kg bw. Radioactivity is
distributed primarily to the gastrointestinal tract, kidneys, and liver, after single- or multiple-dose oral
administration. After 24 h, > 80% of the radioactivity is
recovered in the urine and < 7% in the feces from all
groups of rats, regardless of dose level. At all dose
levels, a small amount of the dose is distributed to the
fat. At 50 and 500 mg/kg bw, radioactivity could be
measured in animals terminated 3 days after dosing.
Except for the high dose pretreatment group, the major
urinary metabolite is hippuric acid, accompanied by
small amounts of cinnamic and benzoic acid. In the high
dose pretreatment group, benzoic acid is the major
metabolite, suggesting that saturation of the glycine
conjugation pathway occurs at repeated high dose levels
of cinnamaldehyde.
In a study of the effect of dose, species, and sex on the
disposition of [3-14C]cinnamaldehyde (Peters and Caldwell, 1994). A 2.0 or 250 mg/kg bw dose of cinnamaldehyde was administered to groups of male and
female F344 rats (4/group) or CD1 mice (6/group) by
intraperitoneal injection. Regardless of the dose level,
species, or sex, greater than 85% of the radiolabel is
recovered in the urine and feces within 24 h. Greater
than 90% is recovered after 72 h. When 250 mg/kg bw
of [3-14C]cinnamaldehyde is administered orally to F344
rats, 98% is recovered from the urine (91%) and feces
(7%) within 24 h (Peters and Caldwell, 1994). The effect
of dose on the disposition of [3-14C-d5]-cinnamic acid in
F344 rats and CD1 mice has also been studied. Five
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
dose levels of cinnamic acid in the range from 0.0005
mmol/kg bw to 2.5 mmol/kg bw were given orally to
groups of F344 rats (4/group) or by intraperitoneal
injection to groups of CD1 mice (4/group). After
twenty-four hours, 73–88% of the radioactivity is
recovered in the urine of rats and 78–93% in the urine
of mice. After 72 h, 85–100% of the radioactivity is
recovered from rats mainly in the urine (Caldwell and
Nutley, 1986). In mice, the recovery is 89–100% within
72 h. Only trace amounts of radioactivity are present
in the carcasses, indicating that cinnamic acid is readily and quantitatively excreted at all dose levels (Nutley et al., 1994). In summary, it appears that the
parent alcohol, aldehyde, and acid undergo rapid
absorption, metabolism, and excretion independent of
dose (up to 250 mg/kg bw), species, sex, and mode
of administration.
Cinnamic acid is rapidly absorbed and cleared from
the blood in humans. Eleven adult human subjects each
received a single intravenous dose of cinnamic acid,
equivalent to 5 mg/kg bw. Analysis of the blood reveals
cinnamic acid at 100% of the total dose within 2.5 min,
declining to 0% after 20 min (Quarto di Palo and
Bertolini, 1961).
A 1.5 mmol/kg bw oral dose (243 mg/kg bw) of
methyl cinnamate is rapidly, and almost completely
(95%), absorbed from the rat gut. Methyl cinnamate
was partially hydrolyzed to cinnamic acid in the stomach (9%) and gut (40%). The rate of absorption from
the gut was similar for cinnamic acid and methyl cinnamate. No ester was detected in the peripheral blood
of rabbits or rats dosed with methyl cinnamate. Only
traces were detected in portal and heart blood samples
taken from dosed rats, indicating that almost complete
hydrolysis of methyl cinnamate occurs during intestinal
absorption (Fahelbum and James, 1977).
More sterically hindered esters are also readily
hydrolyzed in vivo. Following administration of a single
250 mg/kg i.p. dose of [3-14C]cinnamyl anthranilate to
both rats and mice, greater than 91% of the radioactivity is eliminated within 24 h for both species
(Keyhanfar and Caldwell, 1996).
reported to be excellent substrates for ADH (Sund and
Theorell, 1963) and ALD (Feldman and Wiener, 1972),
respectively. The urinary metabolites of cinnamyl alcohol and cinnamaldehyde are mainly those derived from
metabolism of cinnamic acid (see Fig. 1).
Fifty-two percent of a 335 mg/kg bw oral dose of
cinnamyl alcohol given to rats (4) is recovered in 0–24 h
in the urine as the glycine conjugate of benzoic acid
(hippuric acid). Ten minor metabolites cumulatively
account for about 10% of the dose (Nutley, 1990).
Administered to mice by intraperitoneal injection, cinnamyl alcohol undergoes functional group oxidation
followed by b-oxidation and cleavage to yield benzoic
acid that is subsequently excreted in the urine as the
glycine conjugate, hippuric acid (Nutley, 1990).
In a study of the effect of species, route and dose on
the metabolism of cinnamaldehyde, doses of 2 and 250
mg trans-[3-14C]cinnamaldehyde/kg bw were given by
i.p. injection to male and female F344 rats and CD1
mice (Peters and Caldwell, 1994). Doses of 250 mg/kg
bw were administered via oral gavage to male rats and
mice only. In both species and via both routes of
administration, the major urinary metabolites form
from oxidation of cinnamaldehyde to cinnamic acid,
3.3. Metabolism
3.3.1. Cinnamyl alcohol and cinnamaldehyde derivatives
The aromatic primary alcohols and aldehydes used as
flavoring substances or formed by the hydrolysis of
esters and acetals are readily oxidized to the corresponding cinnamic acid derivative (see Fig. 1). Human
NAD+ dependent alcohol dehydrogenase (ADH) catalyzes oxidation of primary alcohols to aldehydes
(Pietruszko et al., 1973). Isoenzyme mixtures of NAD+
dependent aldehyde dehydrogenase (ALD) (Weiner,
1980) catalyze oxidation of aldehydes to carboxylic
acids. Aromatic alcohols and aldehydes have been
165
Fig. 1. Metabolism of cinnamyl derivatives.
166
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
which is subsequently oxidized in the b-oxidation pathway. The major urinary metabolite is hippuric acid (71–
75% in mice and 73–87% in rats), accompanied by
small amounts of 3-hydroxy-3-phenylpropionic acid
(0.4–4%), benzoic acid (0.4–3%), and benzoyl glucuronide (0.8–7.0%). The glycine conjugate of cinnamic
acid is formed to a considerable extent only in the
mouse (4–13%). To a small extent, glutathione conjugation of cinnamaldehyde competes with the oxidation
pathway. Approximately 6–9% of either dose is excreted
in 24 h as glutathione conjugates of cinnamaldehyde.
The authors concluded that the excretion pattern and
metabolic profile of cinnamaldehyde in rats and mice are
not systematically affected by sex, dose size, or route of
administration (Peters and Caldwell, 1994).
The toxicokinetic profile of cinnamaldehyde has been
investigated in male F344 rats (Yuan et al., 1992).
Plasma levels of cinnamaldehyde (< 0.1 mg/ml) and cinnamic acid (< 1 mg/ml) are not measurable when rats
(3–6/group) are administered a single oral dose of 50
mg/kg bw of cinnamaldehyde by gavage in corn oil. At
dose levels of 250 and 500 mg/kg bw, plasma levels of
cinnamaldehyde and cinnamic acid are approximately 1
and greater than 10 mg/ml, respectively. The bioavailability of cinnamaldehyde was calculated to be less than
20% at both dose levels. A dose-dependent increase in
hippuric acid, the major urinary metabolite, occurs 6 h
after gavage and continues over the next 18 h. Only
small amounts of cinnamic acid are excreted in the urine
either free or as the glucuronic acid conjugate. Urinary
hippuric acid recovered over 50 h accounted for 72–
81% over the dose range from 50 to 500 mg/kg bw.
Data from different studies suggest that conjugation
of cinnamaldehyde with glutathione is dose-dependent.
Approximately 15% of an oral dose of 250 mg cinnamaldehyde/kg bw administered to rats by gavage is
excreted in the urine as two mercapturic acid derivatives, N-acetyl-S-(1-phenyl-3-hydroxypropyl)cysteine and
N-acetyl-S-(1-phenyl-2-carboxyethyl)cysteine, in a ratio of
four to one. At a dose of 2 mg/kg bw, rats excrete only 6%
of cinnamaldehyde as glutathione conjugates. Approximately 9% of an oral dose of 125 mg cinnamyl alcohol/kg
bw is excreted in the urine as N-acetyl-S-(1-phenyl-3hydroxypropyl)cysteine (Delbressine et al., 1981).
3.3.2. Cinnamic acid
Intracellular cinnamic acid is converted to acylCoA
esters (Nutley et al., 1994). CinnamoylCoA either conjugates with glycine, a reaction catalyzed by N-acyl
transferase, or undergoes b-oxidation eventually leading
to the formation of benzoylCoA. The reactions that
form benzoic acid from cinnamic acid are reversible but
the equilibrium favors formation of the benzoic acid
CoA ester (Nutley et al., 1994). The equilibrium in the
reaction of cinnamylCoA to yield benzoylCoA and
acetylCoA represents a high capacity pathway for the
metabolism of cinnamic acid. BenzoylCoA is in turn
conjugated with glycine, yielding hippuric acid, or the
CoA thioester is hydrolyzed to yield free benzoic acid
which is then excreted (Nutley et al., 1994). CoA thioesters of carboxylic acids are obligatory intermediates in
amino acid conjugation reactions (Hutt and Caldwell,
1990). The reactions in this sequence are of historical
significance in biochemistry, since it was studies on cinnamic acid and fatty acids that revealed the b-oxidation
pathway of fatty acid catabolism (Nutley et al., 1994).
Regardless of dose or species, the b-oxidation pathway
is the predominant pathway of metabolic detoxication
of cinnamic acid in animals.
In an extensive study of the effect of dose on the conversion of cinnamic acid to benzoic acid, six dose levels
in the range of 0.0005–2.5 mmol/kg (ca. 0.08–400 mg/kg
bw) [14C]- or [14C/2H5]-cinnamic acid were administered
orally to male F344 rats or by intraperitoneal injection
to male CD-1 mice. In both species, 84–101% was
recovered within 72 h with the majority (73–93%)
recovered from the urine within 24 h. The metabolites
identified at all dose levels included hippuric acid, benzoyl glucuronide, 3-hydroxy-3-phenyl-propionic acid,
benzoic acid, and unchanged cinnamic acid. The major
metabolite was hippuric acid at all dose levels (44–
77%). At the highest dose given, (2.5 mmol/kg bw) the
percentage of hippuric acid decreased while the percentages of benzoyl glucuronide and benzoic acid
increased. Increased formation of benzoyl glucuronide
(0.5–5%) and free benzoic acid (0.4–2%) at dose levels
above 0.5 mmol/kg bw provide evidence that saturation
of the glycine conjugation pathway occurs at these
higher dose levels. The fact that 3-hydroxy-3-phenylpropionic acid was only slightly changed over the dose
range (0.2–0.9%) supports the conclusion that the boxidation pathway is not capacity-limited up to 2.5
mmol/kg bw cinnamic acid in the male rat (Nutley et al.,
1994). The increasing role of glucuronic acid conjugation relative to glycine conjugation as dose size increases is a general trend observed in the metabolism of
carboxylic acids (Caldwell et al., 1980).
In mice, glycine conjugation of cinnamic acid competes with the b-oxidation pathway, but only at low
dose levels. However, as dose levels increase from
0.0005 to 2.5 mmol/kg bw, urinary hippuric acid
increases from 44 to 67%, while cinnamoylglycine levels
decrease from 29 to 2.4%. These results suggest that
glycine N-acetyl transferase has high affinity but low
capacity for cinnamic acid compared with benzoic acid.
At the highest dose (2.5 mmol/kg bw), an increase in
excreted free benzoic acid (0.8–8.6%) suggests that glycine conjugation of benzoylCoA is also capacity limited
in mice. At all dose levels, the mouse excretes a small
proportion of benzoyl glucuronide, which suggests that
this conjugation reaction is of minimal importance in
this species (Nutley et al., 1994).
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
Like cinnamic acid, the saturated analog, 3-phenyl-1propanol, participates in the same metabolic pathway.
When ring deuterated 3-phenylpropionic acid is administered orally to a human as a single dose (57 mg),
deuterobenzoic acid corresponding to 110% of the dose
is isolated from the alkaline hydrolyzed urine collected
within 100 min of dosing (Pollitt, 1974).
Eleven adult volunteers received single intravenous
doses of cinnamic acid, equivalent to 5 mg/kg bw.
Analysis of the blood plasma revealed cinnamic acid at
100% of the total dose within 2.5 min declining to 0%
after 20 min. Ninety minutes after dosing, urinalysis
revealed hippuric acid, cinnamoylglucuronide, and benzoylglucuronide present in a ratio of 74:24.5:1.5 (Quarto
di Palo and Bertolini, 1961). These data demonstrate
that cinnamic acid is rapidly oxidized to benzoic acid
metabolites, and excreted in the urine of humans.
3.3.3. Ring and chain substituted cinnamyl derivatives
The position and size of ring substituents play a role
in the metabolism of cinnamyl derivatives. Cinnamyl
derivatives containing a-methyl substituents (e.g. amethylcinnamaldehyde, No. 49) participate in the boxidation and cleavage to yield mainly the corresponding hippuric acid derivative. A benzoic acid metabolite
is isolated from the urine of dogs given either amethylcinnamic acid or a-methylphenylpropionic acid
(Kay and Raper, 1924). Substituents greater than C1
located at the alpha- or beta-position, to some extent,
inhibit b-oxidation (Kassahun et al., 1991; Deuel, 1957).
In these cases, there may be direct conjugation of the carboxylic acid with glucuronic acid followed by excretion.
While a-methylcinnamic acid undergoes oxidation to benzoic acid, a-ethyl- and a-propylcinnamic acids are excreted
unchanged (Carter, 1941). a-Ethylcinnamic alcohol and aethylcinnamaldehyde administered orally to rabbits result
in the urinary excretion of a-ethylcinnamic acid, in addition to small amounts of benzoic acid (Fischer and Bielig,
1940). These observations suggest that a-methylcinnamaldehyde undergoes oxidation to benzoic acid while
higher homologues primarily are excreted unchanged or as
the conjugated form of the cinnamic acid derivative.
Ortho (o) ring substituents (e.g. o-methoxycinnamaldehyde, No. 54) selectively inhibit oxidation
of CoA esters of b-hydroxyacids within the b-oxidation
pathway. In these cases, the hydroxyacid derivative is
excreted unchanged as a glycine conjugate. The bhydroxy derivative is a principal metabolite of o-methoxycinnamaldehyde (Samuelsen et al., 1986).
The glycine conjugates of o-methoxycinnamic and omethoxyphenylpropionic acids are principal urinary
metabolites of o-methoxycinnamaldehyde in rats. Relatively large amounts of the b-hydroxylated phenylpropionic acid derivatives are also detected, but only traces
of benzoic and hippuric acid derivatives (i.e., products
of further b-oxidation) are excreted. The detection of
167
relatively large amounts of a b-hydroxylated derivative
suggests that this metabolite is not readily oxidized,
possibly due to steric hinderance of the ortho substituent (Solheim and Scheline, 1973).
In contrast, para (p-) ring substituents (e.g. 3-(p-isopropylphenyl)propionaldehyde, No. 46, and p-methylcinnamaldehyde, No. 48) may not significantly impact
metabolism via b-oxidation. In male albino rats, pmethoxycinnamic acid has been shown to metabolize
mainly to p-methoxybenzoic acid and its corresponding
glycine conjugate (Solheim and Scheline, 1973). Similar
results are reported with 3,4-dimethoxycinnamic acid,
which is meta and para substituted (Solheim and Scheline,
1976). The structurally related substance p-tolualdehyde
metabolizes to p-methylbenzoic acid without any apparent oxidation of the methyl group (Williams, 1959).
Based on these observations, it may be concluded that the
presence of side-chain alkyl substituents greater than C1
and ortho-ring substituents inhibit the b-oxidation pathway. In these cases, the parent acid (cinnamic acid derivative) or an intermediary b-oxidation metabolite (e.g., bhydroxy-3-phenylpropanoic acid derivative) is efficiently
excreted as the glycine or glucuronic acid conjugate.
3.3.4. Cinnamyl anthranilate
Results of a 2-year bioassay with cinnamyl anthranilate stimulated numerous metabolic studies that are
described below (NCI, 1980) (see Carcinogenicity Studies in Section 4.3.1). The results of these studies
demonstrate the presence of the intact ester in the liver
of mice given high dose levels of cinnamyl anthranilate.
At low dose levels in rodents, cinnamyl anthranilate is
hydrolyzed to cinnamyl alcohol and anthranilic acid.
However, at high dose levels (> 500 mg/kg bw/day) in
mice, ester hydrolysis is incomplete, resulting in the in vivo
presence of the intact ester (Keyhanfar and Caldwell,
1996). Saturation of the hydrolysis pathway has only been
observed at high dose levels in mice (Keyhanfar and
Caldwell, 1996; Caldwell and Viswalingam, 1989). A single
dose of 250 mg cinnamyl anthranilate/kg administered by
i.p. injection to both rats and mice. In the rat, 95 and 4%
of the dose are recovered in the 24-h urine as hippuric acid
and benzoic acid, respectively. No unchanged cinnamyl
anthranilate is recovered. In mice, 77% of the dose is
recovered as hippuric acid, 19% as benzoic acid and 2% as
unchanged cinnamyl anthranilate (Keyhanfar and Caldwell, 1996). In a multiple dose study, male mice received
intraperitoneal injections of 5, 10, 20, 50, 100 or 250 mg
cinnamyl anthranilate/kg bw. Over all dose levels, the
relative amounts of hippuric acid and benzoic acid present
in the urine as metabolites is essentially unchanged. However, at dose levels greater than or equal to 10 mg/kg bw,
unhydrolyzed cinnamyl anthranilate is detected in the
urine. The relative amount of cinnamyl anthranilate
increases with increasing dose levels of greater than 10
mg/kg bw (Keyhanfar and Caldwell, 1996).
168
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
In a dietary study, concentrations of 0, 100, 1000,
5000, 15,000 or 30,000 ppm, which corresponds to estimated daily intakes of 15, 150, 750, 2250 or 4500 mg/kg
bw, respectively (FDA, 1993) of cinnamyl anthranilate
were administered in feed to mice for 21 days. The two
highest concentrations correspond to the same dose
levels used in the NTP 2-year bioassay (NCI, 1980). In
both the male and female mice, unchanged cinnamyl
anthranilate is detected in the urine at dietary levels of
greater than or equal to 5000 ppm (ca. 750 mg/kg bw/
day) (Keyhanfar and Caldwell, 1996). There is no evidence of unhydrolyzed ester in the urine of humans
administered a single i.p. injection of 250 mg cinnamyl
anthranilate/kg bw (Keyhanfar and Caldwell, 1996).
Large doses of cinnamyl anthranilate administered to
mice, resulting in saturation of the hydrolysis pathway,
have also been associated with hepatic enzyme induction (Caldwell, 1992). The enzymic basis for the species
differences in metabolism has been studied in hepatic
microsomes of rats, mice, and humans. The results show
that while cinnamyl anthranilate is hydrolyzed relatively
slowly by hepatic microsomes of rat and human, the
ester is essentially unreactive in mouse liver microsomes,
with less than 10% hydrolysis occurring over a 24-h
period (Caldwell, 1992). In mice, cinnamyl anthranilate
was shown to cause a pattern of enzyme induction that
is characteristic of peroxisome proliferation, including
increases in cytochrome P450, lauric acid omega-hydroxylation and peroxisomal fatty-acid oxidation (Viswalingam et al., 1988). Peroxisome proliferation would not
be expected in humans given the absence of the intact
ester in human urine (Keyhanfar and Caldwell, 1996).
Although the lack of hydrolysis exhibited by cinnamyl
anthranilate is not observed for other cinnamyl esters
(Fahelbum and James, 1977; Grundschober, 1977;
Dakin, 1909; Morgareidge, 1962), it resembles the
hydrolytic behavior of other anthranilate esters.
Hydrolysis studies performed in a number of in vitro
systems including simulated intestinal fluid, simulated
stomach juice, and freshly prepared rat liver homogenate
(Gangolli and Shilling, 1968; Longland et al., 1977), in
homogenates of pig liver and jejenum (Grundschober,
1977), and in vivo in the blood of guinea pigs (Pelling et
al., 1980) indicated that methyl anthranilate and methyl
N-methylanthranilate are resistant to ester hydrolysis. It
is anticipated that the anthranilate moiety inhibits ester
hydrolysis leading, in the case of cinnamyl anthranilate,
to elevated in vivo concentrations of ester.
4. Toxicological studies
4.1. Acute toxicity
Oral LD50 values have been reported for 39 of the 55
substances in this group. In rats, LD50 values are in the
range of 1520 to greater than 5000 mg/kg bw, demon-
strating that the oral acute toxicity of these cinnamyl
derivatives is extremely low (Denine and Palanker,
1973; Jenner et al., 1964; Keating, 1972; Levenstein,
1972, 1974, 1975, 1976; Moreno, 1971, 1972, 1973, 1974,
1975, 1976, 1977, 1981, 1982; Opdyke, 1974; Russell,
1973; Schafer et al., 1983; Weir and Wong, 1971; Wohl,
1974; Zaitsev and Rakhmanina, 1974). LD50 values are
in the range of 913 to greater than 5000 mg/kg bw in
mice (Colaianni, 1967; Draize et al., 1948; Harada and
Ozaki, 1972; Levenstein, 1975; Schafer and Bowles,
1985; Zaitsev and Rakhmanina, 1974), and 3130 to
greater than 5000 mg/kg bw in guinea pigs (Draize et
al., 1948; Zaitsev and Rakhmanina, 1974) (see Table 2).
4.2. Short-term toxicity
Studies performed for cinnamyl alcohol, the corresponding aldehyde, two cinnamate esters, two a-alkylsubstituted cinnamaldehyde derivatives, two alkoxysubstituted cinnamaldehyde derivatives, and a mixture
of five cinnamyl derivatives show no evidence of any
toxicity at dose levels exceeding the estimated daily per
capita intake of the respective cinnamyl derivative by at
least three orders of magnitude (see discussion below
and Table 2). Data on the structurally related ester cinnamyl anthranilate is also included, even though it is no
longer used as a flavoring substance (voluntarily discontinued in 1986).
Daily doses of 53.5 mg/kg bw of cinnamyl alcohol
(No. 12), 68 mg/kg bw of cinnamaldehyde (No. 22), or
80 mg/kg bw of ethyl cinnamate (No. 25), each equivalent to 2% of the LD50 for the respective substance,
were each administered in a sunflower oil solution (0.2
ml/100 g bw) to white rats (12 males/group, strain not
identified) by oral intubation once daily for 4 months.
Liver function tests were performed on animals at days
40 and 140. Increased (26%) blood serum fructose diphosphate aldolase activity was observed in the cinnamyl alcohol and ethyl cinnamate group at day 140.
Activity of serum cholinesterase and alanine aminotransferase, as well as levels of blood serum SH groups,
exhibited no change compared to controls. The authors
concluded that none of the three cinnamyl derivatives
caused any significant pathological change in the liver of
rats (Zaitsev and Rakhmanina, 1974).
Groups (10/sex/group) of male and female OsborneMendel rats were maintained on a diet containing either
0 (control), 1000, 2500 or 10,000 ppm cinnamaldehyde
(No. 22) for a total of 16 weeks. These dietary concentrations correspond to average daily intakes of 50,
125, or 500 mg/kg bw/day, respectively (FDA, 1993).
Measurement of body weight and food intake recorded
weekly showed no significant difference between test
and control animals at any dose level. At termination,
hematological examinations revealed normal values. At
necropsy, no differences were reported between major
169
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
Table 2
Acute and short-term toxicity studies for cinnamyl derivatives used as flavor ingredients
Flavoring ingredient
1
1
2
3
4
5
8
10
11
12
12
12
14
15
16
17
18
19
20
22
22
22
22
22
22
22
23
23
3-Phenyl-1-propanol
3-Phenyl-1-propanol
3-Phenylpropyl formate
3-Phenylpropyl acetate
3-Phenylpropyl propionate
3-Phenylpropyl isobutyrate
Methyl 3-phenylpropionate
3-Phenylpropionaldehyde
3-Phenylpropionaldehyde
Cinnamyl alcohol
Cinnamyl alcohol
Cinnamyl alcohol
Cinnamyl formate
Cinnamyl acetate
Cinnamyl propionate
Cinnamyl butyrate
Cinnamyl isobutyrate
Cinnamyl isovalerate
Cinnamyl benzoate
Cinnamaldehyde
Cinnamaldehyde
Cinnamaldehyde
Cinnamaldehyde
Cinnamaldehyde
trans-Cinnamaldehyde
trans-Cinnamaldehyde
Cinnamic acid
Cinnamic acid
23
24
25
25
26
26
27
28
29
30
31
34
36
37
37
38
39
40
43
47
Cinnamic acid
Methyl cinnamate
Ethyl cinnamate
Ethyl cinnamate
Propyl cinnamate
Propyl cinnamate
Isopropyl cinnamate
Allyl cinnamate
Butyl cinnamate
Isobutyl cinnamate
Isoamyl cinnamate
Linalyl cinnamate
Benzyl cinnamate
Phenethyl cinnamate
Phenethyl cinnamate
3-Phenylpropyl cinnamate
Cinnamyl cinnamate
aAmylcinnamyl alcohol
a-Amylcinnamyl acetate
a-Amylcinnamaldehyde
dimethyl acetal
a-Methylcinnamaldehyde
a-Methylcinnamaldehyde
a-Butylcinnamaldehyde
a-Amylcinnamaldehyde
49
49
50
51
Oral acute studies
Short-term studies
Oral LD50 mg/kg
bw (species)
Reference
2300 (Rat)
2250 (Rat)
4000 (Rat)
4700 (Rat)
>5000 (Rat)
>5000 (Rat)
4200 (rat)
5000 (Rat)
913 (mouse)
2675 (Rat)
2000 (Rat)
2000 (Rat)
2900 (Rat)
3300 (Rat)
3400 (Rat)
5000 (Rat)
5000 (Rat)
>5000 (Rat)
4000 (Rat)
3400 (Rat)
3350 (Rat)
2225 (Mouse)
Moreno (1976)
Weir and Wong (1971)
Levenstein (1975)
Moreno (1973)
Moreno (1973)
Levenstein (1975)
Moreno (1981)
Russell (1973)
Schafer and Bowles (1985)
Zaitsev and Rakhamanina (1974)
Moreno (1973)
Opdyke (1974)
Denine and Palanker (1973)
Moreno (1972)
Moreno (1973)
Levenstein (1976)
Moreno (1977)
Moreno (1973)
Moreno (1975)
Schafer et al. (1983)
Zaitsev and Rakhmanina (1974)
Harada and Ozaki (1972)
4454d (Rat)
Levenstein (1976)
>5000 (Rat, Mouse, Zaitsev and Rakhmanina (1974)
Guinea pig)
3400 (Rat)
Zaitsev and Rakhmanina (1974)
2610 (Rat)
Weir and Wong (1971)
4000 (Rat)
Zaitsev and Rakhmanina (1974)
7305e (Mouse)
3130f (Guinea pig)
>5000 (Rat)
1520 (Rat)
>5000 (Rat)
>5000 (Rat)
>5000 (Rat)
>39,040 (Mouse)
3280 (Rat)
5000 (Rat)
>5000 (Mouse)
>5000 (Rat)
4200 (Rat)
4000 (Rat)
>5000 (Rat)
>5000 (Rat)
Draize et al. (1948)
Draize et al. (1948)
Moreno (1982)
Jenner et al. (1964)
Moreno (1977)
Levenstein (1975)
Moreno (1974)
Colaianni (1967)
Levenstein (1972)
Moreno (1975)
Levenstein (1975)
Keating (1972)
Wohl (1974)
Denine and Palanker (1973)
Moreno (1974)
Moreno (1974)
2000 (Rat)
Russell (1973)
4400 (Rat)
3730 (Rat)
Moreno (1977)
Jenner et al. (1964)
51 aAmylcinnamaldehyde
52 a-Hexylcinnamaldehyde
54 o-Methoxycinnamaldehyde
55 p-Methoxy-methylcinnamaldehyde
a
3100 (Rat)
5000 (Rat)
Moreno (1971)
Levenstein (1974)
Species, sexa
Time
NOEL
Reference
(days)/route (mg/kg bw)
Rat, M
120/oral
53.5b
Zaitsev and Rakhmanina (1974)
Rat, M
Rat; M/F
Rat; M/F
Rat; M/F
Rat; M/F
Mouse; M/F
Rat; M/F
120/oral
84/oral
84/oral
91/oral
112/oral
730
730
68
227
103c
625
125
540
200
Zaitsev and Rakhmanina (1974)
Trubeck Laboratories (1958a)
Trubek Laboratories (1958b)
NTP (1995)
Hagen et al. (1967)
NTP (2002)
NTP (2002)
Rat; M/F
Rat; M
Rat; M/F
84/oral
120/oral
84/oral
3c
80
3c
Trubek Laboratories (1958b)
Zaitsev and Rakhmanina (1974)
Trubeck Laboratories (1958b)
Rat, M/F
Rat; M/F
119/oral
133/oral
500
500
Hagen et al. (1967)
Hagen et al. (1967)
Rat; M/F
84/oral
3c
Trubeck Laboratories (1958b)
Rat; M
Rat; M/F
90/oral
84/oral
221
3c
Trubeck Laboratories (1958c)
Trubeck Laboratories (1958b)
Rat; M, F
98/oral
Rat; M,F
90/oral
287.3 (M)
320.3 (F)
6.1 (M)
6.6 (F)
Rat; M,F
90/oral
Rat; M,F
90/oral
Carpanini et al. (1973)
Oser et al. (1965)
47.1 (M)
52.5 (F)
2.43 (M)
Posternak et al. (1969)
2.74 (F)
Posternak et al. (1969)
M=Male; F=Female. If not listed, sex was not specified in the report.
This study was performed at either a single dose or multiple dose levels that produced no adverse effects. Therefore, this dose level is not a true NOEL, but is the
highest dose tested that produced no adverse effects. The actual NOEL would be higher.
c
The test substance was administered as a component of a mixture.
d
Calculated, based on a reported LD50 of 3.57 ml/kg (Levenstein, 1976) and a density of 1.2475 (CRC, 1989).
e
Calculated, based on a reported LD50 of 7 ml/kg (Draize et al., 1948) and a density of 1.0435 (CRC, 1989).
f
Calculated, based on a reported LD50 of 3 ml/kg (Draize et al., 1948) and a density of 1.0435 (CRC, 1989).
b
170
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
organ weights of test and control animals. Gross
examination of the tissue of all animals was unremarkable. Histopathological examination of 6-8 animals,
equally represented by gender, in the high-dose group
revealed a slight hepatocyte swelling and a slight hyperkeratosis of the stomach (Hagan et al., 1967).
Groups of male and female rats (20/sex/group) were
maintained on a diet containing cinnamaldehyde at
levels calculated to result in the approximate daily
intake of either 0 (control), 58, 114, or 227 mg/kg bw for
12 weeks. Observations of general condition and behavior, as well as measurements of bodyweight, food
intake, and efficiency of food utilization were recorded
regularly. No statistically significant differences between
test and control animals were noted. At week 12 of
experimentation, hematological examination revealed
normal blood hemoglobin levels, and urine analysis
revealed the absence of glucose in either sex and only
trace levels of albumin in male urines (attributed to the
possible presence of semen). At necropsy, measurement
of liver and kidney weights revealed no significant difference between test and control groups. Gross examination revealed occasional occurrence of respiratory
infections in animals from all groups. Histopathological
examination revealed no evidence of adverse effects that
could be related to administration of the test substance
(Trubeck Laboratories, 1958a).
In a 13-week study, groups of 10 male and 10 female
F344/N rats were administered 0, 1.25, 2.5, 5.0, or
10.0% microencapsulated cinnamaldehyde in the diet.
These dietary levels correspond to estimated daily
intakes of 0, 625, 1250, 2500 or 5000 mg/kg bw, respectively (FDA, 1993). Necropsies were performed on all
survivors and histopathological examinations were performed on the two highest dose groups and the control
group. There were no early deaths and no cinnamaldehyde-related clinical observations of toxicology. Group
mean terminal body weight values were similar to
untreated controls for the male and the female vehicle
control group. However, the group mean body weight
values decreased for males and females in the 2.5, 5.0, and
10.0% dose groups. Food consumption for treated male
and female rats was depressed during the first study week
and was attributed to taste aversion. Hematological evaluations did not show any overt cinnamaldehyde-related
toxicity. Clinical chemistry parameters that were
increased by treatment included bile salts and alanine
transaminase levels (male and female 10.0% dose group),
suggesting mild cholestasis. There were no morphological
alterations to the liver based on microscopic examination.
Gross necropsy findings were limited to the stomach of
the 2.5, 5.0, and 10.0% dose groups (NTP, 1995).
Charles River CD rats (10–16/group) were maintained
for 90 days on diets containing either o-methoxycinnamaldehyde (No. 54) at levels calculated to result in
the approximate daily intake of 0 (control), or 47.1 mg/kg
bw for males and 52.5 mg/kg bw for females or p-methoxy-a-methylcinnamaldehyde (No. 55) at levels calculated
to result in the approximate daily intake of 2.43 mg/kg bw
for males and 2.74 mg/kg bw for females. Control groups
received basal diets only. Control and test groups, each
consisting of 10–16 male and female Charles River CD
rats, were housed in pairs of the same sex and given ad
libitum access to water and food. The concentration of the
test material in the diet was adjusted during the study to
maintain constant levels of dietary intake. Clinical
observations recorded daily and food consumption and
body weights determined weekly failed to show any differences between test and control animals. Hematological examinations and blood urea determinations
performed on 50% of the animals at week 7 and again
on all animals at week 13 reveal normal values. At
necropsy, measurement of liver and kidney weights
showed no difference in absolute or relative organ weights
between test and control groups. Histopathological
examination on a wide range of tissues and organs failed
to reveal any lesions that could be associated with administration of the test substances (Posternak et al., 1969).
Rats (5/sex/dose) were maintained on a diet containing a-methylcinnamaldehyde (No. 49) at levels calculated to result in an average daily intake of 0, 58, 115 or
221 mg/kg bw for 90 days. Observations of growth and
food intake volume were recorded weekly with results of
regular examinations of physical appearance, behavior,
and efficiency of food utilization. At week 12 of experimentation, urine samples were collected from both male
and females and analyzed for presence of sugar and albumin, and blood samples were taken for determination of
hemoglobin level. Neither measurements of bodyweight,
general observations, hematology, clinical chemistry, urinalysis, nor histopathology revealed any statistically significant differences between test and control animals at
any dietary level (Trubeck Laboratories, 1958c).
Groups of male and female rats (CFE strain; 15/sex/
group) were maintained on a diet containing 0 (control),
80, 400 or 4000 ppm a-amylcinnamaldehyde (No. 51)
for 14 weeks. Additional groups of five male and five
female rats were maintained on diets containing 400 and
4000 ppm -amylcinnamaldehyde for 2 and 6 weeks.
The respective mean dietary intakes over the 14-week
period were reported to be 0, 6.1, 29.9, and 287.3 mg/kg
bw/day for males and 0, 6.7, 34.9, and 320.3 mg/kg bw/
day for females (Carpanini et al., 1973). Measurement
of bodyweight, food and water consumption revealed
no significant differences between treated and control
groups. Hematological examinations (hemoglobin content, hematocrit, erythrocyte and leucocyte counts, and
individual leucocyte counts) and blood chemistry determinations conducted at 2, 6, and 14 weeks revealed
normal values. Reticulocyte counts performed only on
control and the high dose groups showed no significant
differences. Urine analysis performed during the final
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
week of treatment revealed no difference in cell content
and renal concentration tests for test and control
groups. Measurement of organ weights at autopsy
revealed a statistically significant increase in relative
liver weight in males (P < 0.01) and females (P < 0.05) at
the 4000 ppm dietary level after 14 weeks, increased
stomach weights in males at the 400 ppm level after 6
weeks, and increased relative kidney weight in males
(P < 0.01) at 4000 ppm after 14 weeks. The relative
organ weight increases were not associated with any
evidence of histopathology. Microscopic examination of
prepared tissues from all major organs revealed no evidence of histopathological changes that could be associated with administration of the test material in the diet
(Carpanini et al., 1973).
In a study on the same substance, groups of male and
female rats (15/sex) were maintained on a diet containing a-amylcinnamaldehyde (No. 51) at levels calculated
to result in the approximate daily intake of 6.1 mg/kg
bw for males and 6.6 mg/kg bw for females for a total of
90 days. Bodyweight measurements, food consumption,
and observations of general condition were recorded
regularly. Hematological and clinical chemistry examinations were conducted on 8 rats of each sex at week 6
and again on all animals at week 12 of experimentation.
Neither measurements of growth, hematology, clinical
chemistry, nor histopathology at necropsy revealed any
evidence of toxic effects (Oser et al., 1965).
A mixture of flavorings containing 897 ppm cinnamaldehyde (No. 22) and 25 ppm each of methyl cinnamate (No. 24), ethyl cinnamate (No. 25), cinnamyl
cinnamate (No. 39), and a-methylcinnamaldehyde (No.
49) was added to the diet of rats (12/sex/group) for 12
weeks, resulting in the approximate daily intake of 110
mg/kg bw (male) and 119 mg/kg bw (female) [approximately equivalent to 103 mg/kg bw of cinnamaldehyde
and 3 mg/kg bw of each of the other components (FDA,
1993)]. Weekly measurement of body weight and food
intake revealed a decreased weight gain in treated males
compared to controls animals. The decrease was not statistically significant. There was a statistically significant
decrease in efficiency of food utilization for male
(P< 0.01) and female (P< 0.05) test groups compared to
their respective control group. At week 12, measurement
of blood hemoglobin, urinary sugar, and urinary albumin
levels in three animals of each sex revealed normal values.
At necropsy, liver, kidney, and brain weights were within
normal limits for both sexes. Gross examination revealed
no observable differences between test and control groups
(Trubeck Laboratories, 1958b).
Groups (10/sex/group) of male and female OsborneMendel rats were provided a diet containing either 0
(control), 1000, 2500 or 10,000 ppm linalyl cinnamate
(No. 34) for 17 weeks or 0 (control), 1000 or 10,000 ppm
benzyl cinnamate (No. 36) for 19 weeks. These dietary
levels correspond to estimated daily intakes of 0, 50, 125
171
or 500 mg/kg bw per day of linalyl cinnamate or 0, 50 or
500 mg/kg bw per day of benzyl cinnamate, respectively
(FDA, 1993). Diets were prepared weekly. Analysis of
old diet preparations revealed a 4% weekly loss of linalyl cinnamate. Dietary loss of benzyl cinnamate was not
determined. Measurement of body weight and food
intake recorded weekly showed no significant differences between test and control animals at any intake
level. At termination, hematological examinations
revealed no significant differences between test and
control animals. At necropsy, no differences were
reported between major organ weights of test and control animals. Gross examination of tissue of all animals
was unremarkable and histopathological examination
of 6–8 animals, equally represented by gender, from the
high-dose group and the control group revealed no
treatment-related lesions (Hagan et al., 1967).
4.3. Carcinogenicity studies on cinnamyl anthranilate,
cinnamaldehyde, and anthranilic acid
4.3.1. Cinnamyl anthranilate
Groups of 50 F344 rats or 50 B6C3F1 mice of each
sex were fed cinnamyl anthranilate in diets containing 0,
15,000 or 30,000 ppm for 103 weeks and then observed
for an additional 2–3 weeks (NCI, 1980). The dietary
levels of 15,000 and 30,000 ppm are calculated to provide an average daily intake of 2250 and 4500 mg/kg bw
per day, respectively (FDA, 1993). Control groups consisted of 50 untreated rats and 50 untreated mice of each
sex. All surviving animals were terminated and necropsied at 105–107 weeks. Dose-related reductions in mean
body weight gain occurred in all groups of dosed male
and female rats and mice. Mean body weight gains for
high dose groups of both sexes of mice were as much as
30% lower than those for respective control groups
(NCI, 1980).
Pathological findings. Renal non-neoplastic and neoplastic lesions. An increased incidence of chronic renal
inflammation was observed in control (35/48), low- (47/
50) and high-dose (44/49) groups of male rats. An
increased incidence of renal mineralization in the low(17/50) and high-dose group (30/49) was observed in
male rats when compared to controls (0/48). The lower
incidence of renal mineralization (controls, 2/48; low
dose 0/50; high dose, 3/50) and chronic inflammation
(controls, 9/48; low dose 9/50; high dose, 16/50) in all
groups of female rats suggest that renal toxicity is less
pronounced in the female rat than in the male rat. No
increased incidences of renal toxicity or renal neoplasms
were reported for dosed groups of male or female mice.
Tubular adenomas (2/50) and adenocarcinomas (2/
50) of the renal cortex were reported in the high-dose
group of male rats but were not statistically significant
as compared with controls (0/48). No renal tumors were
172
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
observed in control or low-dose groups of male rats or
in any group of female rats or mice. Based on the historical incidence among male controls at the laboratory
(0/634) and the incidence in all laboratories in the NTP
Testing Program (8/1538, 0.37%), the NTP report concluded the following: ‘‘Under the conditions of these 2year dietary studies, there was evidence of carcinogenicity of cinnamyl anthranilate in male F344 rats based on
the increased incidence of renal tubule adenomas and
adenocarcinomas.’’ (NCI, 1980).
Chronic renal nephropathy (i.e., inflammation and
mineralization) and renal tubule neoplasms were reported when cinnamyl anthranilate was administered to
male rats in the diet for 2 years. Although treated
female rats also exhibited a slight increase in the incidence of renal inflammation, they did not show any
renal tubular neoplasms. The data indicate that renal
toxicity and subsequent neoplasms are sex and speciesspecific effects that occur only at chronic high levels of
intake ( > 2000 mg/kg bw/d). The sensitivity of the male
rat to this type of kidney toxicity is apparently due to
spontaneous nephropathy during aging, which may be
exacerbated by administration of high dose levels of the
test material. Similar findings have been observed at
high intake levels of other substances (NTP, 1992,
1993a, 1993b). When species and sex sensitivity are
combined with the facts that dosed groups of male rats
showed significantly lower growth rates (30% lower),
and that the increase in the incidence of neoplasms was
not statistically significant, there is no clear evidence
that the incidence of these neoplasms is related to
administration of cinnamyl anthranilate in the diet. The
renal effects of cinnamyl anthranilate in the male rat are
a species- and sex-specific phenomena and reflect the
sensitivity of the male rat kidney to chronic progressive
nephropathy, focal hyperplasia, and specific tumorigenic responses (Adams et al., 1996, 1998). The relationship of age to the induction of kidney tumors by
various chemical agents in laboratory rodents in now a
well recognized phenomenon (Hard, 1998).
Pancreatic acinar-cell neoplasms in male rats. The incidence of pancreatic acinar-cell adenomas (2/45) and
carcinomas (1/45) was increased in the high-dose males
(3/45; 7%) compared with controls (0/42). The difference was not statistically significant. However, according to the NTP, the incidence of this type of neoplasm in
aging F344 control rats is extremely low [historical
incidence for controls in participating NTP laboratories
(6/1538; 0.28%)]. Therefore, the NTP considered
occurrence of these neoplasms to be related to administration of the test material.
Since completion of the 2-year bioassay with cinnamyl anthranilate, other carcinogenicity studies have
established a relationship between peroxisome proliferation and the appearance of pancreatic acinar-cell
neoplasms in the male F344 rat. The sex-specific phenomenon also has been observed when F344 male rats
were exposed to high dose levels of other peroxisome
proliferators (e.g. butyl benzyl phthalate and hypolipidemic drugs, clofibrate and nafenopin) (Malley et al.,
1995; NTP, 1997a; Reddy and Qureshi, 1979; Svoboda
and Azanoff, 1979). It appears that the effect on the rat
pancreas is secondary to the effect of these substances
on the liver.
The sequence of pancreatic acinar cell hypertrophy,
hyperplasia, and adenomas in male rats is affected by
several factors including steroids, growth factors such as
cholecystokinin (CCK), growth factor receptor, and
diet. Studies show that testosterone stimulates, and
estrogen inhibits, the growth of pancreatic acinar-cell
neoplasms in rats (Lhotse et al., 1987a,b; Sumi et al.,
1989; Longnecker, 1987; Longnecker and Sumi, 1990).
Cholecystokinin has been shown to stimulate adaptive
and neoplastic changes of pancreatic acinar cells
(Longnecker, 1987). The impact of diet on stimulation
of CCK and the subsequent appearance of acinar cell
neoplasms in male rats has also been reported (Longnecker, 1987; NTP, 1997b). In rat bioassays, the corn oil
vehicle has been shown to increase the incidence of
pancreatic acinar call neoplasms (Longnecker, 1987).
Also, the incidence of pancreatic acinar-cell neoplasms
induced by benzyl phthalate was 10/50 for male rats fed
ad libitum, but 0/10 for rats placed on a restricted feed
protocol for 2 years. The latter study clearly demonstrated the effect of excess caloric intake on the incidence of pancreatic acinar cell neoplasms. In summary,
the appearance of these neoplasms is sex, species, dose,
and even diet specific.
Apparently, prolonged peroxisome proliferation inhibits bile flow leading to cholestasis (Lu et al., 2000;
Marrapodi and Chiang, 2000). The cholestasis, in turn,
leads to a decrease in trypsin activity and an increase in
monitor protein in the gut lumen which stimulates cholecystokinin (CCK) (Obourn, 1997a,b). CCK then acts
on CCK receptors on pancreatic acinar cells leading to
hyperplasia and eventually adenomas. This is a high
dose phenomenon in rats and is unlikely to occur in
humans. Several human studies of hypolipidemic drugs
that are recognized peroxisome proliferators in rodents
have failed to show any significant difference in cancer
deaths between treated patients and placebo-treated
group (IARC, 1996). Also, acinar cell neoplasms are
extremely rare in humans. These results are expected,
since humans and rodents show quantitative difference in
their response to peroxisome proliferators. Apparently,
increased CCK levels in humans do not stimulate acinar
cell proliferation, because humans possess a relatively
small number of CCK receptors compared with the rat.
Given this more recent data and the lack of any correspondence between bioassay results and human studies with peroxisome proliferators, it is concluded that
173
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
the increased incidence of acinar-cell neoplasms in the
F344 male rat are associated with peroxisomal proliferation induced by high dose levels of cinnamyl
anthranilate. This effect is specific to the male F344 rat
and, therefore, is not relevant to the human health
assessment of cinnamyl anthranilate.
Hepatocellular neoplasms in mice. Neoplastic and nonneoplastic lesions associated with administration of cinnamyl anthranilate to mice developed principally in the
liver (Table 3). Treated groups of male and female mice
showed evidence of lipoidosis, hemosiderosis, and
hyperplasia of hepatocytes. There was a statistically
significant increase in the incidence of combined hepatocellular adenomas and carcinomas [control, 14/48;
15,000 ppm or 2250 mg/kg bw, 30/50 (P=0.003); 30,000
ppm or 4500 mg/kg bw, 37/47 (P < 0.001)] in male mice
compared with that of the control group (Table 3).
However, the increase in the incidence of hepatocellular
carcinomas (control, 6/48; 15,000 ppm or 2250 mg/kg,
7/50; 30,000 ppm or 4500 mg/kg, 12/47) was not statistically significant. There was a statistically significant
increase in the incidence of hepatocellular carcinomas
[control, 1/50; 15,000 ppm or 2250 mg/kg bw, 8/49
(P=0.014); 30,000 ppm or 4500 mg/kg bw, 14/49
(P < 0.001)] and combined adenomas and carcinomas
[control, 3/50; 15,000 ppm or 2250 mg/kg bw, 20/49
(P < 0.001); 30,000 ppm or 4500 mg/kg bw, 33/49
(P < 0.001)] in dosed groups of female mice. Four highdose and two low-dose females were diagnosed as having both adenomas and carcinomas.
The NTP report concluded the following: ‘‘Based on
increased incidences of hepatocellular adenomas, and
hepatocellular adenomas and carcinomas, cinnamyl
anthranilate was considered carcinogenic for male and
female B6C3F1 mice receiving 15,000 or 30,000 ppm
cinnamyl anthranilate in the diet’’ (NCI, 1980).
Since performance of the original bioassay (NCI, 1980),
additional studies on over 70 substances have established
a direct correlation between the increased incidence of
hepatocarcinogenicity and the induction of peroxisome
proliferation in rodent livers (Ashby et al., 1994). Studies
performed by the European Centre for Ecotoxicity and
Toxicology of Chemicals (ECETOC) (1992) show that
peroxisome proliferators form a discrete category of
rodent liver carcinogens, the carcinogenicity of which
does not involve direct genotoxic mechanisms.
Histological evidence of peroxisome proliferation in
rodents is reflected by an increased peroxisome/mitochondrial ratio which is correlated with increases in
target organ weights, total cytochrome P-450 content,
and activities in microsomal lauric acid hydroxylation,
carnitine acetyl transferase, and cyanide (CN ) insensitive palmitoyl-CoA (Reddy et al., 1980, 1986; Reddy
and Lalwai, 1983; Barber et al., 1987). Peroxisome proliferation is a transcription-mediated process involving
the peroxisome proliferator-activated receptor (PPARa)
in the hepatocyte nucleus. The role of PPARa in the
induction of hepatocarcinogenicity in the mouse has
been clearly established (Peters et al., 1997). Carcinogenicity studies with mice genetically modified to
remove PPARa show no evidence of either peroxisome
proliferation or carcinogenicity. Given that levels of
expression of PPARa in humans is 1–10% of levels found
in the rat or mouse (Palmer et al., 1994, 1998), it is not
unexpected that humans are refractory to peroxisome
proliferation following chronic exposure to potent rodent
peroxisome proliferators. No significant evidence of peroxisome proliferation has been observed in human studies
with several potent hypolipidemic drugs that are peroxisome proliferators (reviewed in Doull et al., 1999; Ashby et
al., 1994). Based on these observations, it is concluded that
the hepatocarcinogenic response in rodents is not relevant
to the human health assessment of cinnamyl anthranilate.
Summary. When the above information is combined
with data on metabolism and enzyme induction, it may
be concluded that hepatic peroxisome proliferation is
both a rodent-specific and dose-dependent phenomenon
induced by the intact ester cinnamyl anthranilate (Viswalingam et al., 1988; Keyhanfar and Caldwell, 1996;
Caldwell, 1992). Specifically, repeated-dose metabolism
studies have shown that above a threshold dose greater
than 500 mg/kg bw/day, intact cinnamyl anthranilate
given i.p. or in the diet to mice shows a dose-dependent
increase in liver weight, total cytochrome P-450, microsomal lauric acid hydroxylation and cyanide (CN )
insensitive palmitoyl-CoA activity, and peroxisome/
mitochondria ratio in hepatic cells (Caldwell, 1992; Viswalingam et al., 1988). These markers for peroxisome
proliferation correspond to dose levels at which saturation of the hydrolysis pathway leads to the presence of
the intact ester in vivo. Therefore, peroxisome proliferation caused by cinnamyl anthranilate is a dosedependent effect. In addition, the results of chronic
Table 3
Incidences of hepatocellular neoplasms associated with administration
of cinnamyl anthranilate to mice in the diet for 2 years
Control
15,000 ppm
30,000 ppm
1. Male Mice
Hepatocellular adenoma
Hepatocellular carcinoma
Combined Ratesa
8/48
6/48
14/48 (29%)
23/50
7/50
30/50 (60%)
25/47
12/47
37/47 (79%)
2. Female Mice
Hepatocellular adenoma
Hepatocellular carcinoma
Combined ratesb
2/50
1/50
3/50 (6%)
12/49
8/49
20/49 (41%)
19/49
14/49
33/49 (67%)
a
Historical incidence for 2-year dietary studies with control groups
(meanstd. dev.): 112/257(47%).
b
Historical incidence: 37/273 (14%).
174
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
studies on the hydrolysis product, anthranilic acid, and
on the intermediary metabolite cinnamyl alcohol, provide additional evidence for this mechanism of action.
4.3.2. trans-Cinnamaldehyde
In a 2-year bioassay on trans-cinnamaldehyde (NTP,
2002), groups of 50 F344/N rats and B6C3F1 mice of
both sexes were administered diets containing 0, 1000,
2100, or 4100 ppm of trans-cinnamaldehyde in modified
corn starch and sucrose microcapsules. The microcapsules
were coated with modified corn starch. The dietary load of
microencapsulated trans-cinnamaldehyde was maintained
at 1.25%. A vehicle control group (50/sex) received placebo microcapsules (1.25%) in the diet and an untreated
control (50/sex) was maintained on the stardard NTP2000 feed. Analysis of the diet every 9–12 weeks demonstrated that the diet was homogeneous throughout the
study. The dietary levels were estimated to provide an
average daily intake of 0, 50, 100 or 200 mg/kg bw of
trans-cinnamaldehyde in rats and 125, 270 or 540 mg/kg
bw of trans-cinnamaldehyde in mice.
Food and water was made available ad libitum to
animals housed either individually (male mice), 2–3 per
cage (male rats) of 5 per cage (female rats and mice). All
animals were observed twice daily and body weights
were recorded initially, on days 8 and 36, and then every
4 weeks to completion of the study. Complete necropsies and histopathological examinations were performed
on all animals at the conclusion of the study. The urine
of randomly selected male and female rats (10/sex/
group) from each treated group was collected and analyzed for hippuric acid, the principal metabolite of
trans-cinnamaldehyde.
Survival in male rats at the highest feeding level (4100
ppm) was greater than that for the vehicle control
group. Mean body weight in males in the 4100 ppm
group and in the 2100 ppm group after week 94 were
less than that of the vehicle control group. Throughout
the study, the rate of hippuric acid excretion reported as
the hippuric acid/creatinine ratio was proportional to
dose, supporting the conclusion that the primary metabolic pathway was not saturated over the 2 years of
exposure in rats. There was no increase in the incidence
of either non-neoplastic or neoplastic lesions in any
group of treated male or female rats.
In mice, there was no dose-related decrease in survival
for either sex of B6C3F1 mice. Mean body weight of the
2100 and 4100 ppm groups was generally less than that
for the vehicle control group. Although squamous cell
papillomas [1(M) and 3(F)] and carcinoma [1(M) and
1(F)] were reported in the 2100 ppm group (4% in males
and 8% in females), the incidence of these lesions was
within the historical control range (0–6%) for animals
maintained on an NTP 2000 diet. Also there was no
significant increase in this type of lesion in the higher
dose group (4100 ppm). Although there was no evidence
of a statistically significant increase in the incidence of
neoplasms in any group treated with trans-cinnamaldehyde, there was a statistically significant decrease in the
incidence of hepatocellular adenomas and carcinomas
in male mice in the 2100 and 4100 ppm groups and a
negative trend in female mice compared with the vehicle
control group. NTP researchers had previously correlated (Haseman et al., 1997) the decreased incidence of
liver neoplasms with decreased body weights in previous
NTP studies using the NTP 2000 diet. The NTP Board
of Scientific Counselors Technical Report Review Subcommittee met for a peer review of the recently issued
draft NTP Technical Report on trans-cinnamaldehyde
(NTP, 2002). The Subcommittee concluded: ‘‘Under the
conditions of these 2-year feed studies there was no evidence of carcinogenic activity of trans-cinnamaldehyde
in male or female F344/N rats exposed to 1000, 2100, or
4100 ppm. There was no evidence of carcinogenic
activity of trans-cinnamaldehyde in male or female
B6C3F1 mice exposed to 1000, 2100, or 4100 ppm.’’
4.3.3. Conclusion
The lack of any evidence of carcinogenicity in either
rats or mice at levels exceeding 4000 ppm of the diet is
consistent with the results of other bioassays in which
aldehydes (e.g. citral) (NTP, 2002) or reactive substances (e.g. benzyl acetate) (NTP, 1993b) were provided in microencapsulated form administered in the
diet. A comparison of the 2-year bioassay results for
dietary administration of microencapsulated cinnamaldehyde to the gavage administration of a structurally related aromatic aldehyde, benzaldehyde (NTP,
1993a), provides a basis for evaluating the effect of
route of administration on selected carcinogenic endpoints, specifically the increased incidence of forestomach papillomas and squamous cell carcinomas in
rodent species. The increased incidence of forestomach
hyperplasia, papillomas and eventually the appearance
of squamous cell carcinomas in gavage studies using
high concentrations of an irritating aldehyde confirm
the impact of the mode of administration on the toxicological sequelae in the rodent forestomach. Future
design of 2-year bioassays studies with low molecular
weight, irritant substances should avoid the use of
gavage as a mode of administration.
The lack of any evidence of carcinogenicity in the 2year bioassay for trans-cinnamaldehyde provides further clarification for the mechanism by which hepatic
neoplasms are induced in B6C3F1 mice exposed to high
dose levels of a related cinnamyl ester, cinnamyl
anthranilate (NCI, 1980). The toxicology data are also
consistent with previously reported dose-dependent
metabolic data on cinnamyl anthranilate.
At low dose levels, cinnamyl anthranilate is adequately hydrolyzed to cinnamyl alcohol and anthranilic
acid (Keyhanfar and Caldwell, 1996). Cinnamyl alcohol
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
is then readily oxidized in the liver to yield cinnamaldehyde, then cinnamic acid, and eventually hippuric acid
(Keyhanfar and Caldwell, 1996; Nutley, 1990; Teuchy et
al., 1971). However, at elevated dietary levels, those
exceeding 15,000 ppm in mice, the hydrolysis of cinnamyl anthranilate approaches saturation leading to
accumulation of unhydrolyzed ester in the liver compartment. This phenomenon is accompanied by a pattern of hepatic enzyme induction that is characteristic of
peroxisome proliferation (Caldwell, 1992; Caldwell and
Viswalingam, 1989; Keyhanfar and Caldwell, 1996;
Viswalingam et al., 1998).
In an earlier GRAS article (Newberne et al., 2000), it
was concluded that the hepatic neoplasms in the
B6C3F1 mouse in the NTP bioassay are secondary
responses to peroxisome proliferation, a rodent-specific
and dose-dependent phenomenon induced by the intact
ester cinnamyl anthranilate (Caldwell, 1992; Caldwell
and Viswalingam, 1989; Keyhanfar and Caldwell, 1996;
Viswalingam et al., 1988). If the intact ester is responsible for induction of peroxisome proliferation and
subsequent appearance of liver neoplasms, then the
hydrolysis products (anthranilic acid and cinnamyl
alcohol) or their liver metabolites (cinnamaldehyde or
cinnamic acid) should show no evidence of hepatocarcinogenicity in bioassay studies in the same species
and strain at similar or higher levels of exposure. The
results of the bioassay studies for trans-cinnamaldehyde
and anthranilic acid support this hypothesis.
An intake of 15,000 ppm (i.e., the LOAEL for peroxisome proliferation in the cinnamyl anthranilate
study) corresponds to a potential production of 7945
ppm of cinnamyl alcohol and 8240 ppm of anthranilic
acid.5 There was no evidence of carcinogenicity reported
when B6C3F1 mice were maintained on diets of 1)
25,000 or 50,000 ppm anthranilic acid 5 days per week
for 78 weeks and then observed for an additional 26–27
weeks (NCI, 1980) or 2) 1000, 2100 or 4100 ppm
microencapsulated trans-cinnamaldehyde for 2 years
(NTP, 2002). The lack of any evidence of hepatocarcinogenicity for the hydrolysis products supports a mechanism of action in which high concentrations of the intact
ester are responsible for the onset of peroxisome proliferation and the eventual appearance of liver tumors.
The FEMA Expert Panel considers that the lack of
any carcinogenic effect in either species of rodent in 2year chronic studies supports the current recognition of
GRAS for trans-cinnamaldehyde for its intended use as
a flavoring substance. The Panel concludes that these
data also support the conclusion that cinnamyl anthranilate is GRAS for its intended use as a flavoring substance given its historically low level of use by the flavor
industry (NAS, 1970). This material was voluntarily
5
Molecular weight alcohol or acid/Molecular weight ester X dietary level (ppm).
175
withdrawn from use as a flavoring substance more than
a decade ago.
4.4. Genotoxicity studies
4.4.1. In vitro
The results of in vitro studies are summarized in
Table 4. Incubation of cinnamaldehyde (trans and
unspecified regiochemistry), cinnamyl alcohol (trans and
unspecified regiochemistry), cinnamic acid, a-methylcinnamaldehyde, cinnamyl acetate, benzyl cinnamate,
cyclohexyl cinnamate, a-amylcinnamaldehyde, a-hexylcinnamaldehyde,
p-methoxy-a-methylcinnamaldehyde,
3-phenylpropionaldehyde,
or
cinnamyl
anthranilate in Salmonella typhimurium, including
strains TA92, TA94, TA97, TA98, TA100, TA102,
TA104, TA1535, TA1537, TA1538, and TA2637 produced no evidence of mutagenicity with a few exceptions. Assays were performed at concentrations ranging
up to 10,000 mg/plate and in some instances the level of
cytotoxicity, both in the absence and presence of metabolic activation (S9 fraction) obtained from the livers of
Aroclor 1254 or methylcholanthrene-induced SpragueDawley rats or Syrian hamsters (Azizan and Blevins,
1995; Dillon et al., 1992; Dunkel and Simon, 1980; Eder
et al., 1980; 1982a, b; 1991; Florin et al., 1980; Fujita
and Sasaki, 1987; Huang et al., 1985; Ishidate et al.,
1984; Kasamaki et al., 1982; Kato et al., 1989; Lijinsky
and Andrews, 1980; Lutz et al., 1980; 1982; Marnett et
al., 1985; Mortelmans et al., 1986; Neudecker et al.,
1983; NTP, 2002; Prival et al., 1982; Sekizawa and Shibamoto, 1982; Tennant et al., 1987; Wild et al., 1983).
A few weakly positive to positive results were reported for cinnamaldehyde in Salmonella typhimurium
strain TA100 using the pre-incubation method (Dillon
et al., 1992; Ishidate et al., 1984; NTP, 2002). However,
the majority of similar studies in strain TA100, including a recent study using a prolonged pre-incubation
time (120 min), and others using the standard plate
incorporation method, did not find any evidence of
mutagenicity in the TA 100 strain (Azizan and Blevins,
1995; Eder et al., 1982a, b; 1991; Kasamaki et al., 1982;
Kato et al., 1989; Lijinsky and Andrews, 1980; Lutz et
al., 1982; Neudecker et al., 1983; Prival et al., 1982;
Sasaki and Endo, 1978; Sekizawa and Shibamoto, 1982).
Ames/Salmonella typhimurium assays using a preincubation method with o-methoxycinnamaldehyde
produced negative to weak positive results (Eder et al.,
1991; Mortelmans et al., 1986). Of these two studies, the
weak evidence of mutagenicity was reported in strain
TA100 with metabolic activation (Mortelmans et al.,
1986) using two different activation systems, whereas
negative results were obtained in strains TA1535,
TA1537, and TA98 both with and without metabolic
activation. In a second study using tester strain TA100,
negative results were reported without metabolic acti-
176
Table 4
In vitro genotoxicity studies for cinnamyl derivatives used as flavoring ingredients
Test system
Test object
Concentration of agent
Results
Reference
10.
10.
12.
12.
12.
12.
12.
12.
12.
15.
22.
22.
22.
22.
22.
3-Phenylpropionaldehyde
3-phenylpropionaldehyde
Cinnamyl alcohol
Cinnamyl alcohol
Cinnamyl alcohol
Cinnamyl alcohol
Cinnamyl alcohol
Cinnamyl alcohol
Cinnamyl alcohol
Cinnamyl acetate
Cinnamaldehyde
trans-Cinnamaldehyde
Cinnamaldehyde
Cinnamaldehyde
trans-Cinnamaldehyde
S. typhimurium TA98, TA100, TA1535, TA1537
Chinese hamster ovary cells
S. typhimurium TA1537, TA1538, TA98, TA100, TA1535
B. subtilis M45 (rec ) & H17 (rec+)
B. subtilis, H17 or M45
B. subtilis M45 (rec ) & H17 (rec+)
E. coli WP2 uvrA
E. coli WP2 uvrA
Chinese hamster ovary cells
Chinese hamster ovary cells
S. typhimurium TA1537, TA1538, TA98, TA100, TA1535
S. typhimurium TA1537, TA98, TA100, TA1535
S. typhimurium TA104
S. typhimurium TA1537, TA92, TA94, TA98, TA100, TA1535
S. typhimurium TA1537, TA1538, TA98, TA100, TA1535
3 mmol/plate (402 mg/plate)
33.3 mM (4468 mg)
3000 mg/plate
21 mg/disk
1.0 mg/disk (1000 mg/disk)
10 ml/disk (10,400 mg/disk)
3000 mg/plate
4.0 mg/plate (4000 mg/plate)
33.3 mM (4468 mg)
33.3 mM (5868 mg)
600 mg/plate
10 mg/plate (10,000 mg/plate)
0.8 mmoles (105 mg)
0.5 mg/plate (500 mg/plate)
500 mg/plate
Negativea
Negativeb
Negativea
Negativeb
Positiveb
Positiveb
Negativeb
Negativeb
Negativeb
Negativeb
Negativea
Negativea
Negativea
Positivea,d
Negativea
Florin et al. (1980)
Sasaki et al. (1989)
Sekizawa and Shibimoto (1982)
Oda et al. (1979)
Sekizawa and Shibimoto (1982)
Yoo (1986)
Sekizawa and Shibimoto (1982)
Yoo (1986)
Sasaki et al. (1989)
Sasaki et al. (1989)
Sekizawa and Shibamoto (1982)
Prival et al. (1982)
Marnett et al. (1985)
Ishidate et al. (1984)
Lijinsky and Andrews (1980)
22.
22.
22.
22.
22.
22.
22.
trans-Cinnamaldehyde
Cinnamaldehyde
trans-Cinnamaldehyde
trans-Cinnamaldehyde
trans-Cinnamaldehyde
trans-Cinnamaldehyde
trans-Cinnamaldehyde
Ames test
Sister chromatid exchange
Ames testc
Rec-assay
Rec-assay
Rec-assay
Mutation
Mutation
Sister chromatid exchange
Sister chromatid exchange
Ames testc
Ames test
Ames test (preincubation method)
Ames test (preincubation method)
Ames test (plate incorporation
and preincubation methods)
Ames test
Ames test (preincubation method)
Ames test (preincubation method)
Ames test (preincubation method)
Ames test (preincubation method)
Ames test (preincubation method)
Ames test (preincubation method)
500 mg/plate
1 mg/ml (1000 mg/ml)
Not reported
100 mg/plate
5 mmoles/plate (661 mg/plate)
333 mg/plate
300 mg/plate
Kasamaki et al. (1982)
Azizan and Blevins (1995)
Kato et al. (1989)
Mortelmans et al. (1986)
Neudecker et al. (1983)
NTP (2002)
NTP (2002)
22.
22.
22.
22.
22.
22.
22.
22.
22.
22.
22.
Cinnamaldehyde
Cinnamaldehyde
Cinnamaldehyde
Cinnamaldehyde
Cinnamaldehyde
Cinnamaldehyde
Cinnamaldehyde
Cinnamaldehyde
Cinnamaldehyde
Cinnamaldehyde
trans-Cinnamaldehyde
Mutation
Mutation
Rec-assay
Rec-assay
Rec-assay
Rec-assay
Sister chromatid exchange
Chromosome aberration assay
Chromosome aberration assay
Chromosome aberration assay
Chromosome aberration assay
E. coli WP2 uvrA
E. coli WP2 uvrA
B. subtilis, H17 or M45
B. subtilis M45 (rec ) & H17 (rec+)
B. subtilis M45 (rec ) & H17 (rec+)
B. subtilis M45 (rec ) & H17 (rec+)
Chinese hamster ovary cells
Chinese hamster fibroblasts
Chinese hamster B241 cells
Chinese hamster B241 cells
Chinese hamster ovary cells
22.
22.
22.
22.
22.
23.
trans-Cinnamaldehyde
Cinnamaldehyde
Cinnamaldehyde
Cinnamaldehyde
Cinnamaldehyde
Cinnamic acid
Chinese hamster ovary cells
Mouse L1210 lymphoma cells
Mouse L1210 lymphoma cells
Chinese hamster V79 cells
Hep-G2 cells
S. typhimurium TA1537, TA1538, TA98, TA100, TA1535
23.
23.
23.
24.
24.
25.
25.
25.
Cinnamic acid
Cinnamic acid
Cinnamic acid
Methyl cinnamate
Methyl cinnamate
Ethyl cinnamate
Ethyl cinnamate
Ethyl cinnamate
Sister chromatid exchange
DNA strand breaks
Cytotoxicity
Mutation
Micronucleus assay
Ames test (plate incorporation
and preincubation methods)
Rec-assay
Rec-assay
Sister chromatid exchange
Rec assay
Sister chromatid exchange
Ames test (preincubation method)
Chromosome aberration
Rec-assay
600 mg/plate
0.8 mg/plate (800 mg/plate)
0.2 mg/disk (200 mg/disk)
10 ml/disk (10,500 mg/disk)
10 ml/disk (10,500 mg/disk)
21 mg/disk
33.3 mM (4401 mg)
0.015 mg/ml (15 mg/ml)
20 nM (2.6 mg)
10 nM (1.3 mg)
18.3 mg/ml
100 mg/ml
6.8 mg/ml
500 mmol (66,080 mg)
10 mg/ml
100 mM (13,216 mg)
500 mg/ml
1000 mg
Negativea
Negativea
Negativea
Negativea
Negativea
Negativea
Negativea
Weakly Positivee
Negativeb
Negativeb
Positiveb
Positiveb
Positivea
Negativeb
Negativeb
Positiveb
Positiveb
Positive
Negativeb
Negativef
Weak Positiveb
Positiveb
Positiveb
Negativeb
Weak Positiveb
Negative
B. subtilis M45 (rec ) & H17 (rec+)
B. subtilis M45 (rec ) & H17 (rec+)
Chinese hamster ovary cells
B. subtilis M45 (rec ) & H17 (rec+)
Chinese hamster ovary cells
S. typhimurium TA1537, TA92, TA94, TA98, TA100, TA1535
Chinese hamster fibroblasts
B. subtilis M45 (rec ) & H17 (rec+)
25 mg/disk
2.0 mg/disk (2000 mg/disk)
33.3 mM (4934 mg)
20 mg/disk
33.3 mM (5401 mg)
5.0 mg/plate (5000 mg/plate)
0.063 mg/l (63 mg/ml)
20 mg/disk
Negativeb
Negativeb
Positiveb
Negativeb
Positiveb
Negative
Equivocalb
Negativeb
S.
S.
S.
S.
S.
S.
S.
typhimurium
typhimurium
typhimurium
typhimurium
typhimurium
typhimurium
typhimurium
TA98, TA100
TA97, TA98, TA100
TA98, TA100, TA104
TA1537, TA98, TA100, TA1535
TA100
TA100, TA1535, TA1537, TA98
TA100, TA102, TA104
Sekizawa and Shibimoto (1982)
Yoo (1986)
Sekizawa and Shibimoto (1982)
Yoo (1986)
Kuroda et al. (1984)
Oda et al. (1979)
Sasaki et al. (1987)
Ishidate et al. (1984)
Kasamaki and Urasawa (1985)
Kasamaki et al. (1982)
Galloway et al. (1987)
Galloway et al. (1987)
Eder et al. (1993)
Moon and Pack (1983)
Fiorio and Bronzetti (1994)
Sanyal et al. (1997)
Lijinsky and Andrews (1980)
Oda et al. (1979)
Yoo (1986)
Sasaki et al. (1989)
Oda et al. (1979)
Sasaki et al. (1989)
Ishidate et al. (1984)
Ishidate et al. (1984)
Oda et al. (1979)
(continued on next page)
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
Agent
Sasaki et al. (1989)
Wild et al. (1983)
Wild et al. (1983)
Florin et al. (1980)
Yoo (1986)
Wild et al. (1983)
Neudecker et al. (1983)
Mortelmans et al. (1986)
Wild et al. (1983)
Wild et al. (1983)
Fujita and Sasaki (1987)
Wild et al. (1983)
Mortelmans et al. (1986)
Wild et al. (1983)
Positiveb
Negative
Negative
Negative
Negativeb
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Positive
Negative
f
e
d
c
With and without metabolic activation,
Without metabolic activation.
Method included both plate incorporation (without metabolic activation) and preincubation method (with metabolic activation).
Positive results in strain TA 100 only.
Only in strain TA100 with mouse S9.
With metabolic activation.
b
a
TA1537, TA1538
TA1537
TA1537, TA1538
TA1537
TA1537, TA1538
TA1537, TA1538
TA1537, TA1538
Chinese hamster ovary cells
S. typhimurium TA98, TA100, TA1535,
S. typhimurium TA98, TA100, TA1535,
S. typhimurium TA98, TA100, TA1535,
B. subtilis M45 (rec ) & H17 (rec+)
S. typhimurium TA98, TA100, TA1535,
S. typhimurium TA100
S. typhimurium TA98, TA100, TA1535,
S. typhimurium TA98, TA100, TA1535,
S. typhimurium TA98, TA100, TA1535,
S. typhimurium TA97, TA102
S. typhimurium TA98, TA100, TA1535,
S. typhimurium TA98, TA100, TA1535,
S. typhimurium TA98, TA100, TA1535,
Sister chromatid exchange
Ames test
Ames test
Ames test
Rec-assay
Ames test
Ames test (preincubation method)
Ames test (preincubation method)
Ames test
Ames test
Ames test (preincubation method)
Ames test
Ames test (preincubation method)
Ames test
25.
28.
33.
36.
36.
40.
49.
49.
49.
51.
51.
52.
54.
55.
Ethyl cinnamate
Allyl cinnamate
Cyclohexyl cinnamate
Benzyl cinnamate
Benzyl cinnamate
a-Amylcinnamyl alcohol
a-Methylcinnamaldehyde
a-Methylcinnamaldehyde
a-Methylcinnamaldehyde
a-Amylcinnamaldehyde
a-Amylcinnamaldehyde
a-Hexylcinnamaldehyde
o-Methoxycinnamaldehyde
p-Methoxy-alpha-methylcinnamaldehyde
Test system
Agent
Table 4 (continued)
Test object
TA1537, TA1538
TA1537, TA1538
TA1537
33.3 mM (5868 mg)
3.6 mg/plate (3600 mg/plate)
3.6 mg/plate (3600 mg/plate)
3 mmol/plate (715 mg/plate)
1.0 mg/disk (1000 mg/disk)
3.6 mg/plate (3600 mg/plate)
4 mmoles/plate (585 mg/plate)
500 mg/plate
3.6 mg/plate (3600 mg/plate)
3.6 mg/plate (3600 mg/plate)
1.0 mg/plate (1000 mg/plate)
3.6 mg/plate (3600 mg/plate)
666 mg/plate
3.6 mg/plate (3600 mg/plate)
Reference
Concentration of agent
Results
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
177
vation (Eder et al., 1991). No standard plate incorporation Ames test data were available for o-methoxycinnamaldehyde, which may be expected to behave
similarly to the other cinnamyl compounds based on
structural and metabolic similarities.
There was no evidence of mutagenicity in assays
(several using the pre-incubation method) in which
Escherichia coli strains WP2 uvrA, PQ37, and Sd-4-73
were incubated with cinnamaldehyde, cinnamyl alcohol,
cinnamic acid, a-methylcinnamaldehdye, and a?amylcinnamaldehyde (Eder et al., 1991; 1993; Kato et al.,
1989; Ohta et al., 1986; Sekizawa and Shibamoto, 1982;
Szybalski, 1958; Yoo, 1986).
In the Rec assay in Bacillus subtilis, overall positive
results were reported for cinnamaldehyde and cinnamyl
alcohol, whereas cinnamic acid, ethyl cinnamate, methyl
cinnamate, and benzyl cinnamate gave negative results
in all tests using this assay (Kuroda et al., 1984; Oda et
al., 1979; Sekizawa and Shibamoto, 1982; Yoo, 1986).
Assays in isolated mammalian cells produced mixed but
positive results for cinnamyl esters overall. Cinnamaldehyde produced equivocal to positive results in the
forward mutation assay in L5178Y mouse lymphoma
cells both with and without metabolic activation, but
the reports describing these tests did not provide sufficient details on the methodology, test concentrations, or
cytotoxic effects to adequately evaluate the results (Palmer, 1984; Rudd et al., 1983). In L1210 mouse lymphoma cells, DNA strand breaks were observed, but
only at cytotoxic concentrations of cinnamaldehyde
(Eder et al., 1993).
Tests for the induction of sister chromatid exchange
(SCE) in Chinese hamster ovary (CHO) cells exposed to
cinnamaldehyde produced negative results at low concentrations and weakly positive results at concentrations approaching cytotoxic levels, suggesting only weak
SCE activity (Galloway et al., 1987; Sasaki et al., 1987).
A dose-dependent increase in SCE was reported only
when cultures were pre-treated with mitomycin C
(Sasaki et al., 1987); however, in the absence of SCE
activity by cinnamaldehyde alone, the activity in conjunction with mitomycin contributes little to the evaluation of the potential SCE activity. Cinnamaldehyde
was reported to induce chromosome aberrations at low
concentrations (i.e., < 15 mg/ml) in Chinese hamster
fibroblasts and B241 cells tested with and without
metabolic activation (Ishidate et al., 1984; Kasamaki et
al., 1982; Kasamaki and Urasawa, 1985). However,
higher concentrations were negative in CHO cells, both
with and without metabolic activation in a well-conducted, repeated assay (Galloway et al., 1987). Transformation assays showed mixed activity for
cinnamaldehyde, with positive results obtained at nearcytotoxic concentrations or after multiple generations of
growth, and with negative results obtained in human
HAIN-55 cells (Kasamaki et al., 1987; Matthews et al.,
178
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
1993). Subcutaneous injection of these transformed cells
into nude mice led to the formation of nodules at the
site of injection and neoplastic growth in the spleen
(Kasamaki et al., 1987). Negative results were obtained
with cinnamaldehyde in the mutation assay in Chinese
hamster V79 cells (Fiorio and Bronzetti, 1994), while a
weakly positive increase in the incidence of micronucleated Hep-G2 cells was reported (Sanyal et al.,
1997).
Cinnamyl anthranilate did not increase chromosomal
aberrations (ABS) or the frequency of chromatid
breaks and exchanges (SCE) in Chinese hamster ovary
cells with or without metabolic activation at concentrations of 40 or 30 mg/ml, respectively (Tennant et
al., 1987).
The results with the other cinnamyl compounds in
isolated mammalian cells were, in general, comparable
to those obtained with cinnamaldehyde. SCE was not
observed in CHO cells exposed to cinnamyl alcohol,
cinnamic acid, ethyl cinnamate, methyl cinnamate, cinnamyl acetate, or 3-phenylpropionaldehyde. Pretreatment with mitomycin C resulted in increased SCE in
assays with cinnamic acid, methyl cinnamate, and ethyl
cinnamate but not cinnamyl alcohol, cinnamyl acetate,
or 3-phenylpropionaldehyde (Sasaki et al., 1989). Cinnamyl alcohol, cinnamic acid, cinnamyl cinnamate, and
o-methoxycinnamaldehyde have been reported to
produce a dose related increase in the incidence of
reversions in L5178Y mouse lymphoma cells with and
without metabolic activation (Palmer, 1984).
Results of the L5178Ytk mouse lymphoma cells
(MLA) assay have yielded equivocal results. Cinnamyl
anthranilate induced an increase in trifluorothymidine
resistance when incubated at a concentration of 10 mg/
ml with metabolic activation, but showed no mutagenic
activity without metabolic activation (Tennant et al.,
1987). No mutagenic activity was detected in a MLA
assay performed at 40 mg/ml without S-9 activation.
With S-9 activation, mutational frequency increased but
only at concentrations approaching those causing cytolethality (18–31 mg/ml) (Myhr and Caspary, 1991).
Other reports (Palmer, 1984; Rudd et al., 1983) of positive responses in the MLA assay failed to report concentration and cytolethality data.
The positive results obtained in MLA assays were at
near-lethal concentrations in studies reporting cell lethality. The results of the MLA for simple aliphatic and
aromatic substances have been shown to be inconsistent
with the results of other standardized genotoxicity
assays (Heck et al., 1989; Tennant et al., 1987). Culture
conditions of low pH and high osmolality, which may
occur upon incubation with substances (aldehydes, carboxylic acids, lactones, hydrolyzed esters) having a
potentially acidifying influence on the culture medium,
have been shown to produce false-positive results in this
and other assays (Heck et al., 1989).
4.4.2. In vivo
The results of in vivo studies are summarized in Table 5.
The majority of information relating to in vivo administration of cinnamyl compounds pertains to cinnamaldehyde. An increase in the frequency of sex-linked recessive
lethal mutations was reported when Drosophila melanogaster was injected with 20,000 ppm cinnamaldehyde.
However, no increase in the frequency of mutations
occurred when Drosophila melanogaster were fed 800 ppm
cinnamaldehyde for 3 days. Reciprocal translocations
were not observed in either assay (Woodruff et al., 1985).
In mammalian test systems, there was no evidence of an
increase in unscheduled DNA synthesis in hepatocytes
when rats or mice were administered 1000 mg cinnamaldehyde/kg bw by oral gavage (Mirsalis et al., 1989). In
the rodent micronucleus assay, the frequency of micronuclei was not increased when rats or mice were given
1700 mg/kg bw or 1100 mg/kg bw, respectively, of cinnamaldehyde by oral gavage (Mereto et al., 1994) or when
mice were administered 500 mg/kg bw by intraperitoneal
injection (Hayashi et al. 1984, 1988). The frequency of
micronucleated bone marrow cells in mice that had been
exposed to X-rays decreased after 500 mg cinnamaldehyde was administered by injection (Sasaki et al., 1990).
In one study (Mereto et al., 1994), an increase in
micronucleated cells was reported in rat and mouse
hepatocytes, and in rat (but not in mouse) forestomach
cells after oral gavage dosing with up to 1100 (rats) or
1700 (mice) mg cinnamaldehyde/kg bw. No increase in
liver or forestomach micronuclei were observed at dose
levels less than or equal to 850 mg/kg bw. No DNA
fragmentation was observed in the rat hepatocytes or
gastric mucosa cells. An increase in the incidence and
size of GGT-positive foci in hepatocytes of rats pretreated with N-nitrosodiethylamine and then administered 500 mg cinnamaldehyde/kg bw/day by oral gavage
for 14 days was observed (Mereto et al., 1994).
The positive in vivo findings with cinnamaldehyde in
the rat forestomach and in the liver of both rats and
mice are inconsistent with negative results observed in
the standard bone marrow assays or peripheral blood
assays and are observed at dose levels that far exceed
those resulting from intake of cinnamaldehyde in foods.
It has been reported that cinnamaldehyde given at oral
doses of greater than or equal to 500 mg/kg bw results
in the depletion of hepatocellular glutathione levels
(Swales and Caldwell, 1991, 1992, 1993). Therefore,
increases in micronuclei were reported at dose levels
(1100 and 1700 mg/kg bw) that appear to affect cellular
defense mechanisms (i.e., glutathione depletion). Based
on the fact the micronuclei formation is dose-dependent, it appears that induction of micronuclei is a
threshold phenomenon, which occurs at intake levels
orders of magnitude greater than intake of cinnamaldehyde as a flavoring ingredient. Also, the bolus doses
resulting from gavage administration likely produce
Table 5
In vivo genotoxicity studies for cinnamyl derivatives used as flavoring substances
Test system
Test object
Concentration of agent
Results
Reference
22. trans-Cinnamaldehyde
Sex-linked recessive
lethal mutations
Sex-linked recessive
lethal mutations
Reciprocal translocation
mutations
Sex-linked recessive
lethal mutations
Sex-linked recessive
lethal mutations
Sex-linked recessive
lethal mutations
Sex-linked recessive
lethal mutations
Sex-linked recessive
lethal mutations
Unscheduled DNA
synthesis
Drosophila melanogaster
800 ppm (800 mg/g)
Negative
Woodruff et al. (1985)
Drosophila melanogaster
20,000 ppm (20,000 mg/g)
Positive
Woodruff et al. (1985)
Drosophila melanogaster
20,000 ppm (20,000 mg/g)
Negative
Woodruff et al. (1985)
Drosophila melanogaster
1 mM (188,000 mg)
Negative
Wild et al. (1983)
Drosophila melanogaster
45 mM (9,194,000 mg)
Negative
Wild et al. (1983)
Drosophilia melanogaster
5 mM (731,000 mg)
Negative
Wild et al. (1983)
Drosophila melanogaster
10 mM (2,023,000 mg)
Negative
Wild et al. (1983)
Drosophila melanogaster
10 mM (2,163,000 mg)
Negative
Wild et al. (1983)
Rat and mouse hepatocytes
1,000,000 mg/kg
Negative
Mirsalis et al. (1989)
500,000 mg/kg
4,950,000 mg/kg
1,700,000 mg/kg (mice)
1,100,000 mg/kg (rats)
1,700,000 mg/kg (mice)
1,100,000 mg/kg (rats)
1,700,000 mg/kg (mice)
1,100,000 mg/kg (rats)
1,100,000 mg/kg
Negative
Negative
Hayashi et al. (1984,1988)
NTP (2002)
Positive
Mereto et al. (1994)
Negative
Negative (mice)
Positive (rat)
Negative
Mereto et al. (1994)
Mereto et al. (1994)
500,000 mg/kg/dayb
Positive
Mereto et al. (1994)
282,000 mg/kg
510,000 mg/kg
438,000 mg/kg
1,213,000 mg/kg
756,000 mg/kg
Negative
Negative
Negative
Negative
Negative
Wild et
Wild et
Wild et
Wild et
Wild et
22. trans-Cinnamaldehyde
22. trans-Cinnamaldehyde
28. Allyl cinnamate
40 a-Amylcinnamyl alcohol
49. a-Methylcinnamaldehyde
51. a-Amylcinnamaldehyde
52. a-Hexylcinnamaldehyde
22. Cinnamaldehyde
22. Cinnamaldehyde
22. trans-Cinnamaldehyde
22. trans-Cinnamaldehyde
Micronucleus assay
Micronucleus assay
Micronucleus assay
Mouse bone marrow cells
Mouse peripheral blood cells
Rat and mouse hepatocytes
22. trans-Cinnamaldehyde
Micronucleus assay
Rat and mouse bone marrow
22. Cinnamaldehyde
Nuclear anomaliesa
22. trans- cinnamaldehyde
DNA fragmentation
22. Cinnamaldehyde
Induction of
hyperplastic foci
Micronucleus assay
Micronucleus assay
Micronucleus assay
Micronucleus assay
Micronucleus assay
Rat and mouse forestomach
mucosa cells
Rat hepatocytes and gastric
mucosa cells
Rat hepatocytes
28. Allyl cinnamate
40. a-Amylcinnamyl alcohol
49. a-Methylcinnamaldehyde
51. a-Amylcinnamaldehyde
52. a-Hexylcinnamaldehyde
a
b
Mouse bone marrow cells
Mouse bone marrow cells
Mouse bone marrow cells
Mouse bone marrow cells
Mouse bone marrow cells
Mereto et al. (1994)
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
Agent
al. (1983)
al. (1983)
al. (1983)
al. (1983)
al. (1983)
Includes%micronuclei, pyknosis, and karyorrhexis.
Rats were initiated with N-nitrosodiethylamine then administered cinnamaldehyde by oral gavage for 14 consecutive days.
179
180
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
much greater exposures to both the forestomach and
liver, as compared with dietary admixture administration. The authors (Mereto et al., 1994) acknowledged
these facts and concluded that the data did not justify
the conclusion that cinnamaldehyde was clastogenic. As
a result of the apparent threshold for micronuclei
induction and the lack of activity in the remainder of
the in vivo studies, the results obtained with bolus, highdose exposures occurring in the liver and forestomach
are not considered relevant to the safety of cinnamaldehyde from use as a flavoring ingredient. In a more
recent study (NTP, 2002) no increase in micronucleated
peripheral blood cells was observed when B6C3F1 mice
(5/dose/sex) were maintained on diets supplemented
with 0 (control), 4100, 8200, 16,500 or 33,000 ppm daily
for 3 months. These dietary levels correspond to average
daily intakes of 0, 615, 1230, 2475 or 4950 mg/kg bw per
day (FDA, 1993).
In other submammalian and mammalian in vivo tests,
Wild et al. (1983) reported negative results in the sexlinked recessive lethal mutation assay in Drosophila
melanogaster and in the micronucleus assay in mouse
bone marrow cells, each after the administration of
a-methylcinnamaldehyde, allyl cinnamate, a-amylcinnamyl alcohol, a-amylcinnamaldehyde, or a-hexylcinnamaldehyde.
Cinnamyl anthranilate did not induce sex-linked
recessive lethal mutations or reciprocal translocations in
male Drosophila melanogaster when incorporated into
the diet at 5 mM for three days (Wild et al., 1983). No
sex-linked recessive lethal mutations were observed
when male Drosophila melanogaster were maintained on
5000 ppm cinnamyl anthranilate for three days or were
given 2000 ppm cinnamyl anthranilate by intraperitoneal injection daily for three days (Foureman et al.,
1994).
Cinnamyl anthranilate was administered to male
F344/N rats at a dose level of 1000 mg/kg bw. Pancreatic cells failed to exhibit any evidence of unscheduled DNA synthesis (Steinmetz and Mirsalis, 1984). No
increase in micronucleated polychromatic erythrocytes
(PE) was observed 30 hours after groups male and
female NMRI mice (5/dose/sex) were given single intraperitoneal injections of 2533, 1901, or 761 mg cinnamyl
anthranilate/kg bw (Wild et al., 1983). No increase in
micronucleated PE was reported when male B6C3F1
mice were given 500, 1000 or 2000 mg cinnamyl
anthranilate/ kg bw daily by intraperitoneal injection
for three consecutive days (Shelby et al., 1993).
4.4.3. Conclusion
Cinnamyl alcohol and related compounds lack direct
mutagenic or genotoxic activity, as indicated by the
negative results obtained in bacterial test systems. The
mixed results in the Rec assay and in the various antimutagenicity studies are associated with cytotoxicity, as
noted by Sekizawa and Shibamoto (1982). Evidence of
genotoxic activity was observed in isolated mammalian
cells, with the cinnamyl compounds producing chromosome aberrations and/or mutations in the respective test
systems regardless of the presence or absence of metabolic activation; however, the reported in vitro activity
did not translate into mutagenic, clastogenic, or genotoxic activity in vivo.
4.5. Other relevant studies
Female rats were orally administered a 53.5 mg/kg bw
dose of cinnamyl alcohol (No. 12) on either day 4
(implantation) or on days 10–12 (organogenesis) of
gestation. On day 20 of gestation, all animals were terminated and fetuses removed for examination. Neither
measurements of fetal bodyweight, length, nor survival
number revealed any significant differences between test
and control animals. Histopathological examinations
revealed a slight reduction in skeletal ossification of the
extremities. Examination of the sagital sections revealed
no anomalies in relation to palatal structure, eyes,
brain, or other internal organs (Maganova and Saitsev,
1973).
In a second study, female rats were orally administered a 53.5 mg/kg bw dose of cinnamyl alcohol once
per day for the entire course of pregnancy. On day 20 of
gestation, 50% of animals from both test and control
groups were terminated and the fetuses removed for
examination. Neither measurements of fetal bodyweight, liver nucleic acids, number of survivors, nor
examination of bone development revealed any significant differences between test and control animals.
The remaining females from both groups delivered normally. Neither measurements of offspring bodyweight,
survival number, nor size and general development at
birth or at one month revealed significant differences
between test and controls (Zaitsev and Maganova,
1975).
Rats were administered 5, 25 or 250 mg/kg bw/day
cinnamaldehyde (No. 22) by gavage in olive oil on days
7–17 of gestation. A control group was included; however, it was not stated whether or not the controls
received the olive oil vehicle. The number of dams treated per group was 15, 14, 16, and 15 for the control,
low-, mid-, and high-dose groups, respectively. Fetal
abnormalities observed included: poor cranial ossification in all dose groups; increased incidences of dilated
pelvis/reduced papilla in the kidney as well as dilated
ureters in the low- and mid-dose groups; and an
increase in the number of fetuses with two or more
abnormal sternebrae in the mid-dose group. However,
these effects were not dose related and may be attributed to a decrease in maternal weight gain that was
noted in the mid- and high-dose groups (Mantovani et
al., 1989).
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
Female rats were orally administered 0, 5 or 50 mg cinnamic acid (No. 23)/kg bw once daily for the entire course
of pregnancy. On day 20 of gestation, 50% of the females
from all groups were terminated and the fetuses removed
for examination. Fetal body weight measurements, number of survivors, bone development, and hepatic nucleic
acids were determined and no significant differences
between test and control animals were noted. The remaining females from both treated and control groups delivered
normally on days 22–23 of gestation. Neither measurements of offspring bodyweight, size, survival number, nor
general development at birth or one month following
revealed any significant differences between test and control animals (Zaitsev and Maganova, 1975).
5. Recognition of GRASr status
The group of cinnamyl derivatives discussed here was
determined to be generally recognized as safe (GRAS)
under conditions of intended use as flavor ingredients
by the FEMA Expert Panel in 1965. In 1978, the Panel
evaluated the available data and affirmed the GRAS
status of these flavor ingredients (GRASa). In 1993, the
Panel initiated a comprehensive program to reevaluate
the status of all FEMA GRAS flavor ingredients concurrent with a systematic revision of the FEMA Scientific Literature Reviews (SLRs). The group of cinnamyl
derivatives was reaffirmed as GRAS (GRASr) based, in
part, on their self-limiting properties as flavoring substances in food; their rapid absorption, metabolic detoxication, and excretion in humans and other animals; their
low level of flavor use; the wide margins of safety between
the conservative estimates of intake and the no adverse
effect levels determined from subchronic and chronic
studies and the lack of significant genotoxic and mutagenic potential. This evidence of safety is supported by
the fact that the intake of cinnamyl derivatives as natural
components of traditional foods is much greater than
their intake as intentionally added flavoring substances.
6. Correction
In the Safety Assessment of allylalkoxybenzene derivatives used as flavor ingredients–methyl eugenol and
estragole published by FCT in 2002, the publication was
erroneously referred to as the seventh in the series. That
publication was actually the sixth publication in the
series of safety evaluations performed by FEMA’s
Expert Panel.
References
Adams, T.B., Hallagan, J.B., Putnam, J.M., Gierke, T.L., Doull, J.,
Munro, I.C., Newberne, P., Portoghese, P.S., Smith, R.L., Wagner,
181
B.M., Weil, C.S., Woods, L.A., Ford, R.A., 1996. The FEMA
GRAS assessment of alicyclic substances used as flavour ingredients. Food and Chemical Toxicology 34, 763–828.
Adams, T.B., Greer, D.B., Doull, J., Munro, I.C., Newberne, P., Portoghese, P.S., Smith, R.L., Wagner, B.M., Weil, C.S., Woods, L.A.,
Ford, R.A., 1998. The FEMA GRAS assessment of lactones used as
flavour ingredients. Food and Chemical Toxicology 36, 249–278.
Anders, M.W., 1989. Biotransformation and bioactivation of xenobiotics by the kidney. In: Hutson, D.H., Caldwell, J., Paulson, G.D.
(Eds.), Intermediary Xenobiotic Metabolism in Animals. Taylor
and Francis, New York, pp. 81–97.
Ashby, J., Brady, A., Elcombe, C.R., Elliot, B.M., Ismael, J., Odum,
J., Tugwood, J.D., Kettle, S., Purchase, I.F.H., 1994. Mechanisitically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Human and Experimental
Toxicology 13 (Suppl. 2), S1–S118.
Azizan, A., Blevins, R.D., 1995. Mutagenicity and antimutagenicity testing of six chemicals associated with the pungent properties of specific
spices as revealed by the Ames Salmonella/microsomal assay. Archives
of Environmental Contaminants and Toxicology 28, 248–258.
Barber, E.D., Astill, B.D., Moran, E.J., Schneider, B.F., Gray, T.J.B.,
Lake, B.G., Evans, J.G., 1987. Peroxisome induction studies on
seven phthalate esters. Toxicology and Industrial Health 3, 7–24.
Caldwell, J., 1992. Problems and opportunities in toxicity testing arising from species differences in xenobiotic metabolism. In: Chambers, P.L., Chambers, C.M., Bolt, H.M., Preziosi, P. (Eds.),
Toxicology from Discovery to Experimentation to the Human Perspective. Elsevier, New York, pp. 651–659.
Caldwell, J., Idle, J., Smith, R.L., 1980. The amino acid conjugations.
In: Gram, T.E. (Ed.), The Extrahepatic Metabolism of Drugs and
Other Foreign Compounds. SP Medical and Scientific Books, New
York, pp. 453–492.
Caldwell, J., Nutley, B., 1986. Comparative metabolism of cinnamic
acid in rats and mice and its variation with dose. British Journal of
Pharmacology 88 (Suppl), 423.
Caldwell, J., Viswalingam, A., 1989. A comparative study of the
hepatic effects of cinnamyl esters in mice. In: Fifth International
Congress of Toxicology.
Carpanini, F.M.B., Gaunt, I.F., Wright, M.G., Grasso, P., Gangolli,
S.D., 1973. Short-term toxicity of amyl cinnamic aldehyde in rats.
Food and Cosmetics Toxicology 11, 725–734.
Carter, H.E., 1941. The oxidation of branched-chain fatty acids. Biological Symposia 5, 47–63.
Colaianni, L.J., 1967. Acute toxicity, eye and skin irritation tests on
aromatic compounds. Private communication to Research Institute
for Fragrance Materials.
CRC. In: Lide, D.R. (Ed.), CRC Handbook of Chemistry and Physics
Seventieth ed. CRC Press, Boca Raton, FL.
Dakin, H.D., 1909. The mode of oxidation in the animal organism of
phenyl derivatives of fatty acids. Part IV. Journal of Biological
Chemistry 6, 203–209.
Delbressine, L., Klippert, P., Reuvers, J., Seutter-Berlage, F., 1981.
Isolation and identification of mercapturic acids of cinnamic aldehyde and cinnamyl alcohol from urine of female rats. Archives of
Toxicology 49, 57–64.
Denine, E.P., Palanker, A., 1973. Acute Oral and Dermal Toxicity
Studies. Unpublished Report to Research Institute for Fragrance
Materials.
Deuel, H.J., 1957. The oxidation and metabolism of triglycerides, fatty
acids, and glycerol in the animal body. In: The Lipids, Their
Chemistry and Biochemistry, vol. III, Wiley Interscience, New
York, pp. 71–99, 291–301.
Dillon, D.M., McGregor, D.B., Combes, R.D., Zeiger, E., 1992.
Detection of mutagenicity in Salmonella of some aldehydes and
peroxides. Environmental and Molecular Mutagenesis 19, 15.
Doull, J., Cattley, R., Elcombe, C., Lake, B.G., Swenberg, J., Wilkinson, C., Williams, G., van Gemert, M., 1999. A cancer risk
182
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
assessment of di(2-ethyhexyl)phthalate: Application of the new U.S.
EPA risk assessment guidelines. Regulatory Toxicology and Pharmacology 29, 327–357.
Draize, J.H., Alvarez, E., Whitesell, M.F., Woodward, G., Hagen,
E.C., Nelson, A.A., 1948. Toxicological investigations of compounds proposed for use as insect repellents. Journal of Pharmacology and Experimental Therapeutics 93, 26–39.
Dunkel, V., Simon, V., 1980. Mutagenic activity of chemicals
previously tested for carcinogenicity in the National Cancer
Institute Bioassay program. IARC Scientific Publications 27,
283–302.
ECETOC, 1992. Hepatic Peroxisome Proliferation. Monograph 17.
European Centre for Ecotoxicity and Toxicology of Chemicals,
Brussels. (Self-published).
Eder, E., Neudecker, T., Lutz, D., Henschler, D., 1980. Mutagenic
potential of allyl and allylic compounds: Structure-activity relationship as determined by alkylating and direct in vitro mutagenic
properties. Biochemical Pharmacology 29, 993–998.
Eder, E., Neudecker, T., Lutz, D., Henschler, D., 1982a. Correlation
of alkylating and mutagenic activities of allyl and allylic compounds: Standard alkylation test vs. kinetic investigation. ChemicoBiological Interactions 38, 303–315.
Eder, E., Henschler, D., Neudecker, T., 1982b. Mutagenic properties
of allylic and ab-unsaturated carbonylic compounds: consideration
of alkylating mechanisms. Xenobiotica 12, 831–848.
Eder, E., Deininger, C., Muth, D., 1991. Genotoxicity of p-nitrocinnamaldehyde and related ab-unsaturated carbonyl compounds in
two bacterial assays. Mutagenesis 6, 261–269.
Eder, E., Scheckenbach, S., Deininger, C., Hoffman, C., 1993. The
possible role of ab-unsaturated carbonyl compounds in mutagenesis
and carcinogenesis. Toxicology. Letters 67, 87–103.
Fahelbum, I., James, S., 1977. The absorption and metabolism of
methyl cinnamate. Toxicology 7, 123–132.
Feldman, R.I., Weiner, H., 1972. Horse liver aldehyde dehydrogenase.
I. Purification and characterization. Journal of Biological Chemistry
247, 260–266.
Fiorio, R., Bronzetti, G., 1994. Effects of cinnamaldehyde on survival
and formation of HGPRT- mutants in V79 cells treated with methyl
methanesulfonate, N-nitroso-N-methylurea, ethyl methanesulfonate
and UV light. Mutation Research 324, 51–57.
Fischer, F.G., Bielig, H.J., 1940. On the hydrogenation of unsaturated
materials in the animal body. Hoppe-Seylers Zeitschrift fur Physiologische Chemie 266, 73–98.
Florin, I., Rutberg, L., Curvall, M., Enzell, C.R., 1980. Screening of
tobacco smoke constituents for mutagenicity using the Ames’ test.
Toxicology 18, 219–232.
FDA (Food and Drug Administration) 1993. Priority-based assessment of food additives (PAFA) database. Center for Food Safety
and Applied Nutrition.
Foureman, P., Mason, J., Valencia, R., Zimmering, S., 1994. Chemical
mutagenesis testing in Drosophila. Results of 70 coded chemicals
tested for the National Toxicity Program. Environmental and
Molecular Mutagenesis 23, 208–227.
Fujita, H., Sasaki, M., 1987. Mutagenicity test of food additives with
Salmonella typhimurium TA 97 and TA 102(II). Ann Rep Tokyo
Metr Res Lab P.H 38, 423–430.
Galloway, S.M., Armstrong, M.J., Reuben, C., Colman, S., Brown,
B., Cannon, C., Bloom, A.D., Nakamura, F., Ahmed, M., Duk, S.,
Rimpo, J., Margolin, B.H., Resnick, M.A., Anderson, B., Zeiger,
E., 1987. Chromosome aberrations and sister chromatid exchanges
in Chinese hamster ovary cells: Evaluations of 108 chemicals.
Environmental and Molecular Mutagenesis 10 (Supp. 10), 1–175.
Gangolli, S.D., Shilling, W.H., 1968. Hydrolysis of Esters by Artificial
Gastric and Pancreatic Juices. Research Report No. 11/1968. Private communication to FEMA.
Goodwin, T.W., Mercer, E.I., 1972. The Plant Cell Wall. In Introduction to Plant Biochemistry. Pergamon Press, Oxford.
Grundschober, F., 1977. Toxicological assessment of flavoring esters.
Toxicology 8, 387–390.
Hagan, E.C., Hansen, W.H., Fitzhugh, O.G., Jenner, P.M., Jones,
W.I., Taylor, J.M., Long, E.L., Nelson, A.A., Brouwer, J.B., 1967.
Food flavorings and compounds of related structure. II. Subacute
and chronic toxicity. Food and Cosmetics Toxicology 5, 141–157.
Harada, M., Ozaki, Y., 1972. Pharmacological studies on Chinese
cinnamon. I. Central effects of cinnamaldehyde. Journal of the
Pharmaceutical Society, Japan 92, 135–140.
Hard, G.L., 1998. Mechanisms of chemically induced renal carcinogenesis in laboratory rodents. Toxicologic Pathology 26, 104–112.
Haseman, J.K., Young, E., Eustis, S.L., Hailey, J.R., 1997. Bodyweight tumor incidence correlations in long-term rodent carcinogenicity studies. Toxicologic Pathology 25, 256–263.
Hayashi, M., Sofuni, T., Ishidate Jr., M., 1984. A pilot experiment for
the micronucleus test. The multi-sampling at multi-dose levels
method. Mutation Research 141, 165–169.
Hayashi, M., Kishi, M., Sofuni, T., Ishidate Jr., M., 1988. Micronucleus tests in mice on 39 food additives and eight miscellaneous
chemicals. Food and Chemical Toxicology 26, 487–500.
Heck, J., Vollmuth, T., Cifone, M., Jagannath, D., Myrh, B., Curren,
R., 1989. An evaluation of food flavoring ingredients in a genetic
toxicity screening battery. The Toxicologist 9, 257.
Heymann, E., 1980. Carboxylesterases and amidases. In: Jakoby,
W.B. (Ed.), Enzymatic Basis of Detoxication. Academic Press, New
York, pp. 291–323.
Huang, M., Chang, R.L., Wood, A.W., Newmark, H.L., Sayer, J.M.,
Yagi, H., Jerina, D.M., Coney, A.H., 1985. Inhibition of the
mutagenicity of bay-region diol-epoxides of polycyclic aromatic
hydrocarbons by tannic acid, hydroxylated anthraquinones and
hydroxylated cinnamic acid derivatives. Carcinogenesis 6, 237–
242.
Hutt, A.J., Caldwell, J., 1990. Amino acid conjugations. In: Mulder,
G.J. (Ed.), Conjugation Reactions in Drug Metabolism. Taylor and
Francis, Ltd, London, pp. 273–305.
International Agency for Research in Cancer (IARC), 1990. Hypolipidaemic Drugs 66, 390–485.
Ishidate Jr., M., Sofuni, T., Yoshikawa, K., Hayashi, M., Nohmi, T.,
Sawada, M., Matsuoka, A., 1984. Primary mutagenicity screening
of food additives currently used in Japan. Food and Chemical
Toxicology 22, 623–636.
Jenner, P.M., Hagan, E.C., Taylor, J.M., Cook, E., Fitzhugh, O.G.,
1964. Food flavorings and compounds of related structure. I. Acute
oral toxicity. Food and Cosmetics Toxicology 2, 327–343.
Kasamaki, A., Urasawa, S., 1985. Transforming potency of flavoring
agents in Chinese hamster cells. Journal of Toxicolical Sciences 10,
177–185.
Kasamaki, A., Yasuhara, T., Urasawa, S., 1987. Neoplastic transformation of Chinese hamster cells in vitro after treatment with flavoring agents. Journal of Toxicological Sciences 12, 383–396.
Kasamaki, A., Takahashi, H., Tsumura, N., Niwa, J., Fujita, T.,
Urasawa, S., 1982. Genotoxicity of flavoring agents. Mutation
Research 105, 387–392.
Kassahun, K., Farrell, K., Abbott, F., 1991. Identification and characterization of the glutathione and N-acetylcysteine conjugates of
(E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic
acid, in rats and humans. Drug Metabolism and Disposition 19,
525–535.
Kato, F., Araki, A., Nozaki, K., Matsushima, T., 1989. Mutagenicity
of aldehydes and diketones. Mutation Research 216, 366–367.
Kay, H., Raper, H., 1924. The mode of oxidation of fatty acids with
branched chains III. Biochemical Journal 18, 153–160.
Keating, J.W., 1972. Acute Toxicity Study in Rats and Rabbits.
Unpublished Report to Research Institute for Fragrance Materials.
Keyhanfar, F., Caldwell, J., 1996. Factors affecting the metabolism of
cinnamyl anthranilate in the rat and mouse. Food and Chemical
Toxicology 34, 241–249.
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
Kuroda, K., Tanaka, S., Yu, Y.S., Ishibashi, T., 1984. Rec-assay of
food additives. Nihon Koshu Eisei Zasshi (Jpn Soc Pub Health) 31,
277.
Levenstein, I., 1974. Acute Toxicity Study in Rats and Rabbits.
Unpublished Report to Research Institute for Fragrance Materials.
Levenstein, I., 1975. Acute Toxicity Studies in Rats, Mice, and Rabbits. Unpublished Report to Research Institute for Fragrance
Materials.
Levenstein, I., 1976. Acute Oral Toxicity Study in Rats and Acute
Dermal Toxicity Study in Rabbits. Unpublished Report to Research
Institute for Fragrance Materials.
Levenstein, I. 1972. Acute Toxicity Studies in Rats and in Rabbits.
Unpublished Report to Research Institute for Fragrance Materials.
Lhoste, E.F., Roebuck, B.D., Brinck-Johnsen, T., Longnecker, D.S.,
1987a. Effect of castration and hormone replacement on azaserineinduced pancreatic carcinogenesis in male and female Fischer rats.
Carcinogenesis 8, 699–703.
Lhoste, E.F., Roebuck, B.D., Stern, J.E., Longnecker, D.S., 1987b.
Effect of orchiectomy and testosterone on the early stages of azaserine-induced pancreatic carcinogenesis in the rat. Pancreas 2, 38–43.
Lijinsky, W., Andrews, A.W., 1980. Mutagenicity of vinyl compounds
in Salmonella typhimurium. Teratogenesis Carcinogenesis and
Mutagenesis 1, 259–267.
Longland, R.C., Shilling, W.H., Gangolli, S.D., 1977. The hydrolysis
of flavouring esters by artificial gastrointestinal juices and rat tissue
preparations. Toxicology 8, 197–204.
Longnecker, D.S., 1987. Interface between adaptive and neoplastic
growth in the pancreas. Gut 28, 253–258.
Longnecker, D.S., Sumi, C., 1990. Effects of sex steroid hormones on
pancreatic cancer in the rat. International Journal of Pancreatology
7, 159–165.
Lu, Y., Onda, M., Uchida, E., Yamamura, S., Yanagi, K., Matsushita, A., Kobayashi, T., Fukuhara, M., Tajiri, T., 2000. The cytotoxic
effects of bile acids in crude bile on human pancreatic cancer cell
lines. Surg Today 30, 903–909.
Lucas, C.D., Putnam, J.M., Hallagan, J.B., 1999. Flavor and Extract
Manufacturers Association (FEMA) of the United States 1995
Poundage and Technical Effects Update Survey. (Self-published),
Washington DC.
Lutz, D., Neudecker, T., Eder, E., 1980. Mutagenic effects of allylic
alcohols and their corresponding aldehydes. Naunyn-Schmiedebergs
Archives of Pharmacology 311 (Suppl.), R25. (Abstr. No. 97).
Lutz, D., Eder, E., Neudecker, T., Henschler, D., 1982. Structuremutagenicity relationship in ab-unsaturated carbonylic compounds
and their corresponding allylic alcohols. Mutation Research 93,
305–315.
Maarse, H., Visscher, C.A., Willemsens, L.C., Boelens, M.H., 1999.
Volatile Components in Food-Qualitative and Quantitative Data.
Centraal Instituut Voor Voedingsonderzioek TNO, Zeist, The
Netherlands.
Maganova, N., Saitsev, A., 1973. Study of the embryotoxic action of
some synthetic food flavorings. Voprosy Pitaniia 32 (4), 50–54.
Malley, L.A., Carakostas, M., Hansen, J.F., Rusch, G.M., Kelly,
D.P., Trochimowicz, H.J., 1995. Two-year inhalation toxicity study
in rats with hydrochlorofluorocarbon 123. Fundamental and
Applied Toxicology 25, 101–114.
Mantovani, A., Stazi, A., Macri, C., Ricciardi, C., Piccioni, A.,
Badellino, E., 1989. Pre-natal toxicity study of cinnamic aldehyde in
the Sprague-Dawley rat. Food and Chemical Toxicology 27, 781–786.
Marnett, L.J., Hurd, H.K., Hollstein, M.C., Levin, D.E., Esterbauer,
H., Ames, B.N., 1985. Naturally occurring carbonyl compounds are
mutagens in Salmonella tester strain TA104. Mutation Research
148, 25–34.
Marrapodi, M., Chiang, J., 2000. Peroxisome proliferator-activated
receptor .alpha. (PPAR.alpha.) and agonist inhibit cholesterol
7.alpha.-hydroxylase gene (CYP7A1) transcription. Journal of Lipid
Research 41, 514–520.
183
Matthews, E.J., Spalding, J.W., Tennant, R.W., 1993. Transformation
of BALB/c-3T3 cells: IV. rank-ordered potency of 24 chemical
responses detected in a sensitive new assay procedure. Environmental Health Perspectives Supplement 101 (Suppl. 2), 319–345.
Mereto, E., Brambilla-Campart, G., Ghia, M., Martelli, A., Brambilla, G., 1994. Cinnamaldehyde-induced micronuclei in rodent
liver. Mutation Research 322, 1–8.
Mirsalis, J.C., Tyson, C.K., Steinmetz, K.L., Loh, E.K., Hamilton,
C.M., Bakke, J.P., Spalding, J.W., 1989. Measurement of unscheduled DNA synthesis and s-phase synthesis in rodent hepatocytes
following in vivo treatment: testing of 24 compounds. Environmental and Molecular Mutagenesis 14, 155–164.
Moon, K.H., Pack, M.Y., 1983. Cytotoxicity of cinnamic aldehyde on
leukemia L1210 cells. Drug and Chemical Toxicology 6, 521–535.
Moreno, O.M., 1971. Acute Toxicity Studies in Rats, Mice, Rabbits
and Guinea Pigs. Unpublished Report to RIFM.
Moreno, O.M., 1972. Acute Toxicity Studies in Rats, Mice, Rabbits
and Guinea Pigs. Unpublished Report to RIFM.
Moreno, O.M., 1973. Acute Toxicity Studies in Rats, Mice, Rabbits
and Guinea Pigs. Unpublished Report to RIFM.
Moreno, O.M., 1974. Acute Toxicity Studies in Rats, Mice, Rabbits
and Guinea Pigs. Unpublished Report to RIFM.
Moreno, O.M., 1975. Acute Toxicity Studies in Rats, Mice, Rabbits
and Guinea Pigs. Unpublished Report to RIFM.
Moreno, O.M., 1976. Acute Toxicity Studies in Rats, Mice, Rabbits
and Guinea Pigs. Unpublished Report to RIFM.
Moreno, O.M., 1977. Acute Toxicity Studies in Rats, Mice, Rabbits
and Guinea Pigs. Unpublished Report to RIFM.
Moreno, O.M., 1981. Acute Toxicity Studies in Rats, Mice, Rabbits
and Guinea Pigs. Unpublished Report to RIFM.
Moreno, O.M., 1982. Acute Toxicity Studies in Rats, Mice, Rabbits
and Guinea Pigs. Unpublished Report to RIFM.
Morgareidge, K., 1962. In vitro digestion of four acetals. Private
Communication to FEMA.
Mortelmans, K., Haworth, S., Lawlor, T., Speck, W., Tainer, B., Zeiger, E., 1986. Salmonella mutagenicity tests: II. Results from the
testing of 270 chemicals. Environmental and Molecular Mutagenesis
8, 1–119.
Myhr, B., Caspary, W., 1991. Chemical mutagenesis at the thymidine
kinase locus L5178Y mouse lymphoma cells: results for 31 coded
compounds in the National Toxicology Program. Environmental
and Molecular Mutagenesis 18, 51–83.
National Academy of Sciences (NAS), 1970. Evaluating the Safety of
Food Chemicals. NAS Washington, DC.
National Academy of Sciences (NAS), 1970. Evaluating the Safety of
Food Chemicals. NAS Washington, DC.
National Academy of Sciences (NAS), 1970. Evaluating the Safety of
Food Chemicals. NAS Washington, DC.
National Cancer Institute (NCI), 1980. Bioassay of Cinnamyl
Anthranilate for Possible Carcinogenicity (NCI-CG-TR-196; NTP80-10).
National Toxicology Program (NTP), 1992. Toxicology and Carcinogenesis Studies of Quercetin in F344/N Rats (NTP-TR-409, NIH
Publication No. 92-3140). NTP, Research Triangle Park, NC.
National Toxicology Program (NTP), 1993a. Toxicology and Carcinogenesis Studies of Coumarin in F344/N Rats and B6C3F Mice
(Gavage Studies) (NTP-TR-422; NIH Publication No. 93-3153).
NYP, Research Triangle Park, NC.
National Toxicology Program (NTP), 1993b. Toxicology and carcinogenesis studies of 3,4-dihydrocoumarin in F344/N rats and
B6C3F1 mice (gavage studies) (NTP-TR-423; NIH Publication No.
93-3154). NYP, Research Triangle Park, NC.
National Toxicology Program (NTP), 1995. 13-Week Sub-chronic Study
of trans-Cinnamaldehyde in Fisher F344 Rats. Unpublished Report.
National Toxicology Program (NTP), 1997a. Toxicology and Carcinogenesis Studies of Butyl Benzyl Phthalate in F344/N Rats (Feed
Studies) (NTP-TR- 458; NIH Publication No. 97-3374).
184
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
National Toxicology Program (NTP), 1997b. Effect of Dietary
Restriction on Toxicology and Carcinogenesis Studies in F344/N
Rats and B6C3F1 Mice (NTP-TR -460: NIH Publication No. 973376).
National Toxicology Program (NTP), 2002. Toxicology and Carcinogenesis Studies of trans-Cinnamaldehyde (Microencapsulated)
(Draft NTP TR-514; NIH Publication No. 02-4448).
Neudecker, T., Öhrlein, K, Eder, E., Henschler, D, 1983. Effect of
methyl and halogen substitutions in the aC position on the mutagenicity of cinnameldehyde. Mutation Research 110, 1–8.
Newberne, P., Smith, R.L., Doull, J., Feron, V.J., Goodman, J.I.,
Munro, I.C., Portoghese, P.S., Waddell, W.J., Wagner, B.M., Weil,
C., Adams, T.B., Hallagan, J.B., 2000. GRAS Flavoring Substances
19. Food Technology 54, 66–68, 70, 72–74, 76–84.
Nutley, B.P., 1990. Investigations into the Metabolism of Cinnamic
Acid, Cinnamyl Alcohol, and Cinnamaldehyde in Relation to their
Safety Evaluation. A Dissertation submitted for the Degree of
Doctor of Philosophy in the University of London, Department of
Pharmacology.
Nutley, B., Farmer, P., Caldwell, J., 1994. Metabolism of trans-cinnamic acid in the rat and mouse and its variation with dose. Food
and Chemical Toxicology 32, 877–886.
Obourn, J.D., Frame, S.R., Chiu, T., Solomon, T.E., Cook, J.C.,
1997a. Evidence that A8947 enhances pancreas growth via a trypsin
inhibitor mechanism. Toxicology and Applied Pharmacology 146,
116–126.
Obourn, J.D., Frame, S.R., Bell Jr., R.H., Longnecker, D.S., Elliott,
G.S., Cook, J.C., 1997b. Mechanisms for the pancreatic oncogenic
effects of the peroxisome proliferator Wyeth-14,643. Toxicology and
Applied Pharmacology 145, 425–436.
Oda, Y., Hamano, Y., Inoue, K., Yamamoto, H., Niihara, T., Kunita,
N., 1979. Mutagenicity of food flavors in bacteria. Osaka_Furitsu
Koshu Eisei Kenkyu Hokoku. Shokuhin Eisei Hen 91, 325.
Ohta, T., Watanabe, M., Watanabe, K., Shirasu, Y., Kada, T., 1986.
Inhibitory effects of flavourings on mutagenesis induced by chemicals in bacteria. Food and Chemical Toxicology 24, 51–54.
Opdyke, D.L.J., 1974. Monographs on fragrance raw materials. Cinnamic alcohol. Food Cosmetics Toxicology 12, 855–856.
Oser, B.L., Carson, S., Oser, M., 1965. Toxicological tests on flavoring
matters. Food and Cosmetics Toxicology 3, 563–569.
Palmer, K.A., 1984. L5178Y TK +/ assay of cinnamaldehyde and
several structurally related compounds. Environmental Mutagenesis
6, 423–424.
Palmer, C.A.N., Hsu, M.-H., Muerhoff, A.S., Griffith, K.J., Johnson,
E.F., 1994. Interaction of the peroxisome proliferator-activated
receptor A with the retinoid X receptor A unmasks a cryptic peroxisome proliferator response element that overlaps an ARP-1binding site in the CYP4A6 promoter. Journal of Biological Chemistry 269, 18083–18089.
Palmer, C.A.N., Hsu, M.-H., Griffith, K.J., Raucy, J.L., Johnson,
E.F., 1998. Peroxisome proliferator activated receptor-a expression
in human liver. Molecular Pharmacology 53, 14–22.
Pelling, D., Longland, R., Dulley, M., Gangolli, S.D., 1980. A study
of the intestinal absorption of four flavouring esters in the guinea
pig. BIBRA, Surrey, Great Britain. Private communication.
Peters, M., Caldwell, J., 1994. Studies on trans-cinnamaldehyde. The
influence of dose size and sex on its disposition in the mouse and rat.
Food and Chemical Toxicology 32, 869–876.
Peters, J.M., Cattley, R.C., Gonzalez, F.J., 1997. Role of PPARa in
the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator WY-14, 643. Carcinogenesis 18, 2029–2033.
Pietruszko, R., Crawford, K., Lester, D., 1973. Comparison of substrate specificity of alcohol dehydrogenase from human liver, horse
liver, and yeast towards saturated and 2-enoic alcohols and aldehydes. Archives of Biochemistry and Biophysics 159, 50–60.
Pollitt, R.J., 1974. Phenylpropionic acid in the urine of patients with
phenylketonuria and normals. Clinica Chimica Acta 55, 317–322.
Posternak, J.M., Linder, A., Vodoz, C.A., 1969. Summaries of toxicological data. Toxicological tests on flavoring matters. Food and
Cosmetics Toxicology 7, 405–407.
Prival, M.J., Sheldon Jr., A.T., Popkin, D., 1982. Evaluation, using
Salmonella typhimurium, of the mutagenicity of seven chemicals
found in cosmetics. Food and Chemical Toxicology 20, 427–432.
Quarto di Palo, F.M., Bertolini, A.M., 1961. Cinnamic acid administration to renal patients. Atti Accad. Med. Lombarada 16, 180–183.
Reddy, J.K., Azarnoff, D.L., Hignite, C.E., 1980. Hypolipidaemic
hepatic peroxisome proliferators form a novel class of chemical
carcinogens. Nature 283, 397–398.
Reddy, J.K., Lalwai, N.D., 1983. Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs
and industrial plasticizers to humans. CRC Critical Reviews in
Toxicology 12, 1–58.
Reddy, J.K., Qureshi, S.A., 1979. Tumorigenicity of the hypolipidaemic
peroxisome
proliferator
ethyl-alpha-chlorophenoxyisobutyrate (clofibrate) in rats. British Journal of Cancer 40,
476.
Reddy, J.K., Reddy, M.K., Usman, M.I., Lalwani, N.D., Rao, M.S.,
1986. Comparison of hepatic peroxisome proliferative effect and its
implication of hepatocarcinogenicity of phthalate esters, di(2-ethylhexyl) phthalate, and di(2-ethylhexyl) adipate with a hypolipidemic
drug. Environmental Health Perspectives 65, 317–327.
Rudd, C.J., Mitchell, A.D., Spalding, J., 1983. L5178Y mouse lymphoma cell mutagenesis assay of coded chemicals incorporating
analyses of the colony size distributions. Environmental Mutagenesis 5, 419. (Abstract No. Cd_19)..
Russell, T., 1973. Acute Oral and Dermal Toxicity Studies. Unpublished report to RIFM.
Samuelsen, O., Brenna, J., Solheim, E., Scheline, R., 1986. Metabolism of the cinnamon constituent o-methoxycinnamaldehyde in the
rat. Xenobiotica 16 (9), 845–852.
Sanyal, R., Darroudi, F., Parzefall, W., Nagao, M., Knasmüller, S.,
1997. Inhibition of the genotoxic effects of heterocyclic amines in
human derived hepatoma cells by dietary bioantimutagens. Mutagenesis 12, 297–303.
Sapienza, P., Ikeda, G.J., Warr, P.I., Plummer, S.L., Dailey, R.E.,
Lin, C.S., 1993. Tissue distribution and excretion of 14C-labelled
cinnamic aldehyde following single and multiple oral administration
in male Fischer 344 rats. Food and Chemical Toxicology 31, 253–
261.
Sasaki, Y., Endo, R., 1978. Mutagenicity of aldehydes in Salmonella.
Mutation Research 54, 251–252.
Sasaki, Y.F., Imanishi, H., Ohta, T., Shirasu, Y., 1987. Effects of
antimutagenic flavourings of SCEs induced by chemical mutagens in
cultured Chinese hamster cells. Mutation Research 189, 313–318.
Sasaki, Y.F., Imanishi, H., Ohta, T., Shirasu, Y., 1989. Modifying
effects of components of plant essence on the induction of sisterchromatid exchanges in cultured Chinese hamster ovary cells.
Mutation Research 226, 103–110.
Sasaki, Y.F., Ohta, T., Imanishi, H., Watanabe, M., Matsumoto, K.,
Kato, T., Shirasu, Y., 1990. Suppressing effects of vanillin, cinnamaldehyde, and anisaldehyde on chromosome aberrations induced
by X-rays in mice. Mutation Research 243, 299–302.
Schafer, E.W., Bowles, W.A., 1985. Acute oral toxicity and repellency
of 933 chemicals to house and deer mice. Archives of Environmental
Contamination and Toxicology 14, 111–129.
Schafer, E.W., Bowles, W.A., Hurlbut, J., 1983. The acute oral toxicity, repellency, and hazard potential of 998 chemicals to one or
more species of wild and domestic birds. Archives of Environmental
Contamination and Toxicology 12, 355–382.
Sekizawa, J., Shibamoto, T., 1982. Genotoxicity of safrole-related
chemicals in microbial test systems. Mutation Research 101, 127–
140.
Shelby, M., Erexson, G., Hook, G., Tice, R., 1993. Evaluation of a
three-exposure mouse bone marrow micronucleus protocol: results
T.B. Adams et al. / Food and Chemical Toxicology 42 (2004) 157–185
with 49 chemicals. Environmental and Molecular Mutagenesis 21,
160–179.
Solheim, E., Scheline, R., 1973. Metabolism of alkenebenzene derivatives in the rat. I. r-Methoxyallybenzene (Estragole) and p-Methoxypropenylbenzene (Anethole). Xenobiotica 3, 493–510.
Solheim, E., Scheline, R., 1976. Metabolism of alkenylbenzene derivatives in the rat. II. Eugenol and Isoeugenol methyl esters. Xenobiotica 6, 137–150.
Steinmetz, K., Mirsalis, J., 1984. Measurement of DNA repair in primary cultures of rat pancreatic cells following in vivo treatment.
Environmental Mutagenesis 6, 446.
Stofberg, J., Kirschman, J.C., 1985. The consumption ratio of flavoring materials: a mechanism for setting priorities for safety evaluation. Food and Chemical Toxicology 23, 857–860.
Stofberg, J., Grundschober, F., 1987. Consumption ratio and food
predominance of flavoring materials. Perfumer and Flavorist 12,
27.
Sumi, C., Longnecker, D.S., Roebuck, B.D., Brinck-Johnsen, T.,
1989. Inhibitory effects of estrogen and castration on the early stage
of pancreatic carcinogenesis in Fisher rats treated with azaserine.
Cancer Research 49, 2332–2336.
Sund, H., Theorell, H., 1963. Alcohol dehydrogenases. In: Boyer,
P.D., Lardy, H., Myrback, K. (Eds.), The Enzymes, second ed., vol.
7. Academic Press, New York, pp. 25–83.
Svoboda, D.J., Azarnoff, D.L., 1979. Tumors in male rats fed ethyl
chlorophenoxyisobutyrate, a hypolipidemic drug. Cancer Research
39, 3419–3428.
Swales, N.J., Caldwell, J., 1991. Cytotoxicity and depletion of glutathione (GSH) by cinnamaldehyde in rat hepatocytes. Human
Experimental Toxicology 10, 488–489.
Swales, N.J., Caldwell, J., 1992. Cytotoxicity and glutathione depletion in hepatocytes by esters of cinnamic acid. Human Experimental
Toxicology 6, 589–590.
Swales, N.J., Caldwell, J., 1993. The Depletion of Hepatic Reduced
Glutathione (GSH), Cysteine and Protein Sulphydryls by Cinnamaldehyde in F344 Rats. In: ISSX Proceedings, vol. 3, Fifth European ISSX Meeting, 26–29 September, Tours, France.
International Society for the Study of Xenobiotics, USA.
Szybalski, W., 1958. Special microbiological systems. II. Observations
on chemical mutagenesis in microorganisms. Annals of the New
York Academy of Sciences 76, 475–489.
Tennant, R., Margolin, B., Shelby, M., Zeiger, E., Haseman, J.,
Spalding, J., Caspary, W., Resnick, M., Stasiewicz, S., Anderson,
B., Minor, R., 1987. Prediction of chemical carcinogenicity in
rodents from in vitro genetic toxicity assays. Science 236, 933–941.
Teuchy, H., Quatacker, J., Wolf, G., van Sumere, G.F., 1971. Quantitative investigations of hipurric acid formation in the rat after
185
administration of some possible aromatic and hydroaromatic precursors. Archives of International Physiology and Biochemistry 79,
573–587.
Trubeck Laboratories, 1958a. Toxicological examination of cinnamic
aldehyde in rats. (Class IV, Part 2). Private communication to
FEMA. Unpublished Report.
Trubeck Laboratories, 1958b. Toxicological screening of components
of food flavors. Class IV. Cinnamates. Private communication to
FEMA. Unpublished Report.
Trubeck Laboratories, 1958c. Toxicological examination of methyl
cinnamic aldehyde (ClassIV, Part 3). Private communication to
FEMA. Unpublished Report.
Viswalingam, A., Caldwell, J., Fournel, S., Schladt, L., Oesch, F.,
1988. Hepatic effects of cinnamyl anthranilate resemble those of a
peroxisome proliferator in mouse, but not in rat. British Journal of
Pharmacology 93, 32.
Weiner, H., 1980. Aldehyde oxidizing enzymes. In: Jakoby, W. (Ed.),
Enzymatic basis of Detoxication, vol. 1. Academic Press, New
York.
Weir, R.J., Wong, L.C.K., 1971. Acute Oral and Dermal Toxicity
Studies in Rabbits. Unpublished Report to RIFM.
Wild, D., King, M.T., Gocke, E, Eckhardt, K., 1983. Study of artificial flavouring substances for mutagenicity in the salmonella/
microsome, BASC and micronucleus tests. Food and Chemical
Toxicology 21, 707–719.
Williams, R.T., 1959. Aliphatic Alcohols, Glycols and Polyols; The
Metabolism of some Aliphatic Aldehydes, Ketones and Acids. In
Detoxication Mechanisms: The Metabolism and Detoxication of
Drugs, Toxic Substances, and Other Organic Compounds. Second
ed. Chapman and Hall, London. pp. 46–97.
Wohl, A., 1974. Acute Oral Dermal Toxicity Studies. Unpublished
Report to RIFM.
Woodruff, R.C., Mason, J.M., Valencia, R., Zimmering, S., 1985.
Chemical mutagenesis testing in Drosophila. V. Results of 53 coded
compounds tested for the National Toxicology Program. Environmental Mutagenesis 7, 677–702.
Yuan, J.H., Dieter, M.P., Bucher, J.R., Jameson, C.W., 1992. Toxicokinetics of cinnamaldehyde in F344 rats. Food and Chemical
Toxicology 30, 997–1004.
Yoo, Y.S., 1986. Mutagenic and antimutagenic activities of flavoring
agents used in foodstuffs. Journal Osaka City Medical Center 4,
267–288.
Zaitsev, A.N., Maganova, N.B., 1975. Embryotoxic effects of some
aromatizers for food products. Voprosy. Pitaniia 3, 64–68.
Zaitsev, A.N., Rakhmanina, N.L., 1974. Toxic properties of phenylethanol and cinnamic alcohol derivatives. Voprosy Pitaniia 5, 48–
53.